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Schizophrenia (SZ) is a chronic, common, disabling neuropsychiatric 
disease that affects about 1% of the population. Despite evidence for a 
prominent genetic contribution to risk for SZ, there are relatively few replicated 
positive results. Among the genes that have been identified as possible SZ 
susceptibility genes are ErbB4, NRG1, and the topic of my dissertation, NRG3.  
In 2003, Fallin et al. reported a linkage signal in chromosome 10q22 in a 
rigorously-phenotyped homogeneous Ashkenazi Jewish (AJ) population, and a 
follow-up association study across the linkage peak identified a strong 
association of several intronic SNPs in NRG3 (rs60827755, rs10883866 and 
rs10748842) with the a factor designated “Delusion.” This was one of 9 factors 
derived from a principal component analysis of 73 phenotypic features. 
 
Methods 
 We used next-generation sequencing in a population of patients that 
ranked at the extremes of the delusion score distribution in order to identify 
those variants in the 162 Kb that were most associated with delusion score. Of 
the top-ranking SNPs, five were chosen for dual-luciferase reporter assays to 
test for regulatory potential. 
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 In order to test for nuclear protein binding, we used electrophoretic 
mobility shift assays (EMSAs). We compared binding patterns between alleles 
and determined relative binding strength by competing with unlabeled probe. 
Using an in silico approach, we predicted which known proteins may bind our 
regions of interest, and proceeded to test one by supershift. 
 We also characterized a Nrg3 knockout mouse developed by our 
laboratory. We performed a battery of behavioral tests relevant to models of 
schizophrenia. In order to test whether our mouse has the interneuron 
migration deficits predicted by previous publications, we assayed neuronal 
migration by labeling cells born at E12.5 with EdU, and then immunostaining 
for age-appropriate GABAergic interneuron markers at various developmental 
and postnatal ages.   
 
Results and Conclusions 
 We identified three SNPs that exhibit regulatory potential and are most-
highly associated with our delusion phenotype. We show that all three SNPs 
bind to nuclear proteins and that two of them do so differentially. We then show 
evidence for possible binding of CNOT4 to a 21-bp region of DNA centered 
around rs60827755. Further experiments are required to confirm this 
observation, but we believe that elucidating the pathway whereby NRG3 
mediates its effect on the SZ phenotype will be beneficial in understanding the 
neuronal basis of delusions. 
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 The Nrg3-/- animals exhibit a pervasive hyperactivity phenotype, with 
more subtle deficits in pre-pulse inhibition and startle response. Additional 
findings include decreased anxiety, pre-pulse inhibition and startle response 
deficits, fear and/or emotional- based learning or memory deficits, and 
perturbed working memory. Since these findings are consistent and comparable 
to those of other mouse models for schizophrenia developed by knocking out 
other genes in the NRG/ErbB4 pathway, we conclude that this is a useful 
model for schizophrenia research.  
 Migration assays revealed that the absence of Nrg3 does not lead to a 
depletion of interneurons in several regions of the cortex, but there does appear 
to be a depletion of interneurons in at least one other region (striatum). We 
surmise that a migratory change concentrates GABAergic interneurons in the 
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Chapter 1 : Introduction  
Schizophrenia  
Schizophrenia (SZ) is a chronic, common disabling neuropsychiatric 
disease that affects about 1% of the population.1-3 The age of onset is typically 
in young adulthood and response to treatment is poor. The symptoms of SZ are 
generally classified in three domains: a positive symptom domain that includes 
delusions and hallucinations; a negative symptom domain characterized by 
apathy, alogia, blunted affect and social withdrawal; and a cognitive symptom 
domain that encompasses disorganization in speech and thought.4  
Schizophrenia is a complex genetic disorder, with susceptibility 
determined by both genes and environment. The evidence for a genetic 
contribution to SZ is strong, with a sibling relative risk of 10%, and dizygotic 
and monozygotic twin concordance rates of ~17% and ~50%, respectively.5 
Heritability of SZ is estimated between 60-89%.6,7  
Despite this evidence for a prominent genetic contribution to risk for SZ, 
traditional genetic methods of disease gene identification (linkage and 
association) have produced relatively few replicated positive results, in part 
because of phenotypic variability and genetic (allelic and locus) heterogeneity.2,8-
18 Among the genes that have been identified as possible SZ susceptibility genes 





Neuregulin 3 as a SZ susceptibility gene 
Neuregulin 3 (NRG3) is a strong biological candidate gene for SZ. It is one 
of three paralogs of NRG1, another replicated SZ susceptibility gene.22,23 Like 
NRG1, NRG3 undergoes extensive alternative splicing and alternate utilization of 
first exons (Figure 2-1).  Expression of NRG3 is limited to brain, breast, and 
testis and is higher early in development.22,24 The protein product of NRG3 is a 
single-pass Type I membrane protein with an extracellular N-terminal EGF-like 
domain that is cleaved and binds ErbB4 receptors25-27 encoded by ErbB4, 
another gene implicated in SZ.19-21 Originally thought to function as an 
attractive signaling protein, NRG3 appears to function as a chemorepellant 
signal in patterning and migration of GABAergic interneurons in the developing 
cerebral cortex.28-30 
 In 2003, Fallin et al. 31 reported a linkage signal in chromosome 10q22 
(nonparametric linkage score of 4.27) in a rigorously-phenotyped homogeneous 
Ashkenazi Jewish (AJ) population. This result was independently replicated in 
the Han Chinese population.32  
A follow-up association study across the linkage peak with 9 factors 
(heritability ranging from 0.27-0.60) derived from a principal component 
analysis of 73 phenotypic features was performed in the AJ population and 
identified a strong association (p= 1.6x10-6 – 2.3x10-7) of several intronic SNPs 
in NRG3 (rs6584400, rs10883866 and rs10748842) with the factor designated 
“Delusion.”33,34  
This delusion factor is heavily loaded with positive symptoms of SZ, 
including thought insertion; delusions of influence, guilt and reference; 
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somatic, olfactory and tactile hallucinations; thought withdrawal; thought 
broadcasting; thought echo, primary delusions and primary delusional 
perception.33 This constellation of symptoms closely resembles Schneiderian 
first rank symptoms, and was originally given that name.35 Subjects who score 
highly in the delusion factor tend to exhibit more of these symptoms than other 
patients with schizophrenia.  
The aforementioned association of SNPs in NRG3 with a delusion factor 
was replicated in Western European36 and in Anglo-Irish cohorts.37 In the 
former, the authors suggested a functional role for rs10748842, possibly by 
regulating relative abundance of NRG3 isoforms.36 
 
Thesis Statement 
 The thesis of this dissertation is that variants in NRG3 affect the 
expression and/or splicing of this gene. Regulatory imbalances in NRG3 
absolute levels or relative isoform abundance lead to a predisposition to a 
subtype of SZ that exhibits more types of delusions. This effect is mediated by 
improper neural migration during development and leads to behavioral 
abnormalities seen in other mouse models of SZ.  
  
Contributions  
Despite the replications of the original linkage and association signals, 
NRG3 remains a poorly-studied gene that presents an interesting opportunity to 
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study the modulation of the schizophrenia phenotype. This dissertation aims to 
better understand the genetics of NRG3 and its association with schizophrenia, 
and specifically contributes the following: 
 New, inclusive nomenclature of all known exons of NRG3 
 Identification of causative variants in the association of the NRG3 
gene with the delusion factor 
 Evidence of the regulatory effect of SNPs in NRG3 
 Exploration of putative transcription factors that bind regulatory 
SNPs and thus mediate the effect of NRG3 on schizophrenia 
 Characterization of neurodevelopmental phenotype of a Nrg3 
knockout mouse  
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Abstract 
Schizophrenia (SZ) is a severely disabling psychiatric disorder affecting 
1% of the world’s population. It is both phenotypically and genetically 
heterogeneous. Previously, we reported a linkage peak for SZ (NPL of 4.7) at 
10q22 in the Ashkenazi Jewish (AJ) population and, in a follow-up fine mapping 
association study, found strong evidence of association between the “delusion” 
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factor score of our phenotypic principal component analysis and three intronic 
SNPs in the 5’ end of Neuregulin 3 (NRG3). Independently, two other groups 
have replicated these findings. In aggregate, these results indicate variants in 
NRG3 confer risk for a subtype of schizophrenia with a multiplicity of delusions, 
particularly first rank symptoms. 
To identify the responsible causative variants, we sequenced the 162 kb 
linkage disequilibrium (LD) block covering the 5’ end of NRG3 and containing 
the three associated SNPs in 47 AJ SZ patients at the two extremes of the 
delusion quantitative trait distribution. We identified 5 noncoding SNPs with 
minor alleles on the implicated haplotype that were significantly 
overrepresented in subjects scoring high on the delusion factor. We tested these 
for regulatory effects and found that risk alleles of rs10883866 and rs60827755 
significantly and reproducibly decreased and increased (3-4 fold), respectively, 
the expression of a reporter gene when compared to the alternative allele in 
various cell types. Post-mortem RNA quantification experiments suggest the 
same variants perturb expression of NRG3 isoforms.   In summary, we have 
identified the regulatory single nucleotide variants responsible for the 
association of  NRG3 with delusion symptoms in SZ. 
 
Introduction 
In 2009, Chen et al. 34 reported an association of several SNPs in NRG3 
with a delusion factor heavily-weighted for traits similar to Schniderian First-
rank symptoms. The SNPs with the most significant association (rs10883866, 
rs10748842 and rs6584400) were located in a 162kb linkage disequilibrium 
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(LD) block in the 5’ end of NRG3, which includes the region upstream (5’) of the 
gene, its promoter regions, several exons as well as large introns. This chapter 
describes the efforts to identify and characterize the functional variants 
underlying the association with the delusion factor in the LD block containing 
the associated SNPs.  
 
Materials and Methods 
Nomenclature of NRG3 gene 
A comprehensive literature search was conducted for nomenclature of 
known exons as well as reports of novel exons in NRG3. Unpublished data from 
H. Vernon studying the structure of NRG3 cDNA was added to these reports, 
and the UCSC genome browser (genome.ucsc.edu) was queried for reported 
exons and alternate exon usage. The exons were compared to determine overlap 
between sources, and a comprehensive list of exons generated without regard to 
splicing patterns. 
 
Subject Ascertainment and Factor Analysis 
All of the subjects were participants in the Research Program of the JHU 
Epidemiology-Genetics Program. The ascertainment and assessment of these 
patients and controls has been previously described.31,34,38 
The factor analysis derivation has been previously described.33 For family 
studies, 10 probands were selected based on their heterozygosity for a 1.8kb 
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deletion and availability of DNA and psychiatric history from at least one first-
degree relative.  
 
Next-generation sequencing, analysis parameters and software  
To generate sequencing libraries, we amplified 19 overlapping  ~10kb 
amplicons to cover the entire 162kb LD block using LA Taq (Kyoto, Japan) and 
the following conditions: 2 min at 94°C, 14 cycles of 10 sec at 98°C and 20 min 
at 68°C, 16 cycles of 10 sec at 98°C and 20 min at 68°C, where for each 
additional cycle the time was increased by 15 sec per cycle, and finally a single 
20-min step at 72°C. Fragmentation to approximately 250bp was done using a 
Covaris sonicator (Herts, England). During the library preparation stage, we 
multiplexed samples for library preparation in groups of 12, each including 6 
low delusion and 6 high delusion individuals. Each multiplexed library was 
then sequenced in one or two lanes obtaining 75bp paired-end reads on the 
Illumina Genome Analyzer or the Hi-Seq 2000.  
We aligned the reads using the BWA aligner (version 0.5.9) with default 
settings39  and post-processed aligned reads using the Genome Analysis Toolkit 
(GATK, version 1.0.5336)40 to remove duplicate reads, realign around small 
insertions or deletions (indels) and recalibrate base-call quality scores. We 
excluded one high delusion subject from the analysis due to low coverage depth 
(55) relative to the other samples (average coverage of 850). The median fraction 
of reads that aligned was 90%.  We called single-nucleotide variants (SNVs) and 
indels using samtools mpileup41 (version 0.1.17) on all samples simultaneously 
with parameters -C50 -D -S -d 50000, which were chosen to down weight reads 
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with excessive mismatches and to allow for high depth coverage. We filtered 
variant calls based on software recommendations and performance on 
validation data removing a marker if its overall call quality score was less than 
99 and set individual calls to missing if their call quality was below 40.  
We also assessed quality and depth of coverage differences between our 
groups of interest at each variant, comparing these quantities between low and 
high delusion individuals using a t-test to ensure that differences in sequencing 
effort or variant call quality between the two groups would not produce biased 
results in genotype comparisons. We removed variants with p-values less than 
0.1 on either of these tests, from further consideration. 
We validated a total of 790 known variants across the region in all 
subjects using previously-obtained SNP genotypes at 19 positions34. Of these, 
773 were correctly called from our unfiltered SNV detection, for an accuracy of 
97.8% (95.1% sensitivity, 99.5% specificity using a variant presence/absence 
criteria). After setting all calls with an individual call quality less than 40 or a 
variant call quality less than 99 to missing, 6 incorrect calls remained. This 
accuracy of 99.2% reflects 100% specificity and 98.1% after filtering  
 
Deletion studies 
During the amplification process, we identified a 1.8 kb deletion located 
23 kb upstream of the NRG3 transcriptional start site and genotyped it by PCR 
amplification as follows: 94°C for 3 min, followed by 31 cycles of 94°C for 45 
sec, 60°C for 30 sec, and 72°C for 3 min, and afterwards, 10 min at 72°C. We 
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calculated association of this deletion to the delusion QTL using UNPHASED 
software42. 
In family studies and in other population studies we genotyped the 
deletion using a three-primer assay (Figure 2-5) with a single forward primer 5’ 
of the deletion and two reverse primers, one in the deleted region and one 3’ of 
the deletion. In this assay, a deleted chromosome yields a 249 bp amplicon 
while a non-deleted chromosome yields a 406 bp product. PCR cycling 
conditions were: 94°C for 2 min, followed by 31 cycles of 30 sec at 94°C, 61°C 
and 68°C.  
 
Reporter constructs 
To determine if the deleted region had regulatory activity, we generated 
dual-luciferase reporter assay (DLA) reporter constructs of the genomic region 
of interest by PCR amplification from subjects who were homozygous for either 
the deleted or non-deleted allele. We generated two PCR amplicons: the “WT” 
was 3.8kb and included the region of the deletion plus 1kb flanks on both 
sides;  the “Deleted” construct (Del)  was 2kb and included only the 1kb regions 
flanking the deletion. For the WT construct, we used AccuPrime PCR Systems 
(Invitrogen, Carlsbad, CA) with the following cycling conditions: 94°C for 2 min, 
26 cycles of 30 sec at 94°C, 30s at 57°C and 5 min at 68°C, followed by 5 
additional min at 68°C. For the Del construct, we used Taq Polymerase 
(Invitrogen, Carlsbad, CA). The PCR cycling conditions were: 95°C for 1 min, 31 
cycles of 95°C for 30 sec, 58°C for 30 sec and 72°C for 4 min 20 sec, followed by 
a single step at 72°C for 10 min.  The products were gel-extracted using the 
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QIAquick Spin Kit (Qiagen, Hilden, Germany) and concentrated to at least 
25ng/μl by ethanol precipitation.  
To determine if the deletion had some effect based on spatial 
characteristics of the region, we also made a “Stuffer” construct (Stu) based on 
the Del construct. We utilized a 1.8kb segment of an enhancerless zebrafish 
construct (ZNAS -17.9) previously found to have no enhancer activity in DLAs.43 
To produce the construct we amplified three segments: the 1 kb 5’ flank using a 
reverse primer with an added BamHI site; the 3’ flank using a forward primer 
with an added ClaI site; and the 1.8kb stuffer with a forward primer that 
included a Bam HI site and a reverse primer that included a ClaI site. Cycling 
conditions were: 94°C for 3 min, followed by 31 cycles of 94°C for 45 sec, 60°C 
for 30 sec, and then by 72°C for 3 min, and 10 min at 72°C. We gel-purified the 
amplicons as above, digested, gel extracted again, and ligated equimolar 
amounts. We amplified ligation products using the following PCR cycling 
conditions: 94°C for 3 min, followed by 31 cycles of 94°C for 45 sec, 60°C for 30 
sec, and 72°C for 4 min, and afterwards, 10 min at 72°C and gel-purified 
product. 
To produce constructs containing the single nucleotide variants to be 
tested for regulatory effects, we amplified an approximately 320 bp segment 
including the regions of highest conservation around the variant, using as 
template subjects heterozygous for the SNPs. PCR cycling conditions were: 94°C 
for 3 min, followed by 31 cycles of 94°C for 45 sec, 60°C for 30 sec, and 72°C 
for 3 min, followed by, 10 min at 72°C. The products were gel-purified and 
cloned.  In our sample of individuals, we identified three haplotypes for SNPs 
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rs10883862 and rs7919976, which are 35 bp apart, and generated single 
constructs for each of three haplotypes. Also, we produced a 2.7 kb construct 
combining rs10748842 and rs60827755 by PCR amplification from 2 subjects 
using the following cycling conditions: 3 min at 94°C, 31 cycles of 45 sec at 
94°C, 30 sec at 56.5-63°C, and 3:30 min at 72°C, followed by a single step at 72 
for 10 min. The products were gel-purified and cloned as above.    
 For all constructs, the inserts were cloned using the pCR8/GW/TOPO 
TA Cloning Kit (Invitrogen, Carlsbad, CA) following addition of A bases (7ul of 
DNA, 1 ul of Taq Polymerase, 1ul of 10X PCR Buffer and 1ul of a 12:1:27 
mixture of 50 mM MgCl2: 100mM ATP: water incubated at 72°C for 10 min).  
The recombinant plasmids were harvested from 5mL liquid culture with 
spectinomycin, miniprepped using the QIAprep Miniprep kit  (Qiagen, Hilden, 
Germany), tested by restriction enzyme digest and Sanger sequencing, and the 
inserts shuttled to pDSMA, a Gateway-modified pGL3-promoter plasmid44 using 
LR Clonase Enzyme Mix (Invitrogen, Carlsbad, CA). The transformants were 
cultured in LB media with carbenicillin, miniprepped, and tested by restriction 
enzyme digest and Sanger sequencing. We selected clones with no mutations, 
cultured them in 50 ml LB with carbenicillin, harvested the plasmid  by 
QIAfilter Plasmid Purification Midi Kit (Qiagen, Hilden, Germany) and diluted 
each to 100ng/ul (SNP constructs) or 200ng/ul (all others).  
 
Dual-luciferase  reporter assays 
We cultured HT2245, HEK 293, and Neuro2A lines in Dulbecco’s modified 
Eagle’s medium (DMEM) with Glutamax and 10% FBS. Primary cortical neuron 
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cells from E18 C57BL/6 mice for assays testing the deletion, or E18 SD rat for 
assays testing SNPs were cultured and maintained as described previously.46 To 
minimize cell death, we switched the cultures to medium without antibiotics 24 
hr prior to transfection.  We co-transfected cells with the pGL3 and Renilla 
vectors at a 20:1 ratio using lipofectamine-2000 (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions and lysed the cells 24 hours post-
transfection in passive lysis buffer according to the manufacturer’s instructions 
(Promega, Madison WI) except that we used 20ul of lysate and 50ul of each 
reagent for the assays.    
 
Human brain mRNA studies 
We extracted DNA and total RNA from subjects without macroscopic 
pathology from 190 superior temporal gyrus (STG) samples from the Harvard 
Brain Tissue Resource Center (HBTRC) and 94 dorsolateral prefrontal cortex 
(DLPFC) samples from the National Institute of Child and Human Development 
(NICHD). Samples were genotyped for rs10748842 and rs60827755 by TaqMan 
genotyping assays (Invitrogen, Carlsbad, CA). 
Expression of NRG3 transcripts initiating with exon 1a and exon 1b was 
measured separately, using exon-specific primers for qPCR of cDNA reverse 
transcribed from brain RNA , and was quantified by comparison to a standard 
curve with normalization to the expression of two housekeeping genes, MRIP 
and ACTB, as described.47 The data were log transformed to achieve a normal 
distribution and outliers were removed.  
14 
 
Using a generalized linear model, we interrogated the expression data for 
correlations with genotypes at selected SNPs using age, sex, qPCR plate, 
and post mortem interval as covariates. To examine changes in relative 
abundance of classes of transcripts, we adjusted expression of transcripts 
initiating with exon 1b for that of transcripts initiating with exon 1a. 
 
 
Results and Discussion 
 
Previously, our laboratory had examined 720 AJ SZ probands for 
association between each of 9 quantitative traits (phenotypic principal 
component factor scores) and select genotypes around NRG3. We found 
significant association of the Delusion factor with the genotypes of SNPs in a 
162 kb LD block covering the 5’ end of NRG3.34  Here, we sequenced SZ 
subjects stratified according to their scores on the Delusion quantitative trait 
(QT) with the goal of finding the variant(s) responsible for the association signal.  
High and low delusion subjects differed primarily in the number of types of 
delusions that they exhibited, with high delusion factor subjects experiencing 






Sequencing of the NRG3 5’ 162kb LD block 
To identify all variants across the LD block, we sequenced subjects in 4 
pooled sets of 12 samples (6 from the high and 6 from the low extremes of the 
Delusion QT distribution). The minimum average depth for samples included in 
the analysis was 334, and 98.6% of positions in our region of interest were 
covered by at least 15 reads, which is considered more than sufficient for 
analysis.48 There was no difference between the high and low delusion groups in 
average coverage (t-test p=0.49) or percentage of bases covered by at least 15 
reads (t-test p=0.20). This result indicates that between-sample differences in 
these variables did not bias our subsequent analyses.  
 
A microdeletion upstream of NRG3 is associated with delusions but lacks 
functional consequences  
PCR and sequencing revealed a 1.8 kb microdeletion located 23kb 5’ of 
the predicted transcription start site of NRG3 (Figure 2-2). This previously 
unreported microdeletion is in a region with low sequence conservation. There 
are flanking clusters of transcription factor binding sites (TFBSs), ~ 6kb 5’ and 
~12kb 3’ of the microdeletion. 
 To determine if the microdeletion itself was a causative variant, we first 
measured its frequency in various populations (Table 2-1). We found similar 
frequencies in our sample of AJ SZ (2.65%, n=641), AJ BP (2.57%, n=564) and 
AJ Control (2.8%, n=642) cohorts. However, when we tested SZ patients at both 
extremes of the delusion quantitative trait, we found a significant difference in 
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frequencies (8/138 or 5.8% in the high compared to 0/134 alleles or 0% in low 
delusion patients; Fisher exact test p=0.013). To investigate this association 
with delusion scores in a larger SZ cohort, we genotyped the microdeletion in 
624AJ SZ subjects across the range of delusion scores and found a strong 
association with delusion (genotype effects p=0.006895). We did not detect the 
microdeletion in 346 outbred American European SZ subjects, suggesting that 
it is specific to Ashkenazim. We also genotyped the microdeletion in 10 
unrelated families with heterozygous probands and found that it was inherited 
and had identical breakpoints in all. From these results, we reasoned that the 
microdeletion was either causative or marked a haplotype containing a 
causative variant(s).  
To investigate potential regulatory effects of the microdeletion, we 
performed DLAs in human HEK 293 cells, HT22 cells and cultured mouse 
cortical neurons. We found no difference in relative expression among our 
various reporters, even when we corrected for possible spatial effects by 
introducing an inactive stuffer sequence into our deletion construct (Figure 2-
3). These in vitro experiments suggested that the microdeletion lacks regulatory 
consequences and, more likely, marks a haplotype containing causative 
variant(s). 
 
Identification of variation in cis with the microdeletion 
During the course of these studies, we identified two homozygotes for the 
microdeletion, a BP subject and a non-affected relative of a SZ.  The latter, a 66 
year old asymptomatic woman (98023-3446), has a brother and a nephew with 
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SZ. Sequencing of 98023-3446 revealed homozygosity for all SNPs across the 
entire LD block (Figure 2-2), including the risk alleles of previously identified 
delusion-associated SNPs.34  She has 121 homozygous non-reference variants 
and no heterozygous variants, suggesting that the microdeletion haplotype 
extends across the entire sequenced region. Genotyping 5 other members in her 
family and 31 unrelated affected AJ microdeletion heterozygotes allowed us to 
define three distinct haplotypes across the LD block, one that is marked by the 
microdeletion and likely contains the risk variants and two others without the 
microdeletion that likely do not carry the risk variants.  Sequencing the LD 
block in 24 individuals with high delusion QT scores, 23 with low delusion QT 
score and 98023-3446 identified a total of 620 SNVs in the LD block. Of the 57 
SNVs associated with a high delusion score (p < 0.05) in the present study, 54 
were non-reference alleles homozygous in 98023-3446 and we concluded these 
made up the microdeletion haplotype. 
To assess differences between low and high delusion subjects at each of 
these 54 SNVs, we ranked them according to p-value as calculated by Fisher’s 
exact test (Figure 2-2C and Table 2-2).  While no results withstood correction 
for multiple testing, the 5 nominally most significant (p = 0.003 for all 5, 
MAF=0.104 -0.424) were located in a ~8kb cluster flanking and including exon 
2. Two SNVs (rs10883866 and rs10748842) were among the three previously 
identified to be most associated with the delusion factor.34 The third, 
rs6584400, while not among the most significantly associated SNPs, had a p-
value of 0.015 and was included in our functional studies of a total of 6 





Variants in intronic regions of NRG3 affect NRG3 expression in vitro and ex-vivo  
 To determine if the variant genotype affected regulatory function of the 
surrounding sequence, we performed DLAs testing ~320bp surrounding either 
allele of a SNV in HEK 293, HT22, Neuro2A cell lines, and rat primary cortical 
neurons.  
We tested rs7919976 and rs10883862, which are only 67bp apart 
(R2=0.329), in a single construct and detected no discernible regulatory activity 
(Figure 2-4). Variant rs6584400 had a minimal and inconsistent effect 
regardless of genotype.  For these reasons, we did not perform additional 
studies on these variants. We observed modest effects for rs10748842 with the 
minor allele increasing relative expression by ~1.2 fold. For this reason and 
because this variant was implicated by previous authors based on in silico 
computational analysis, we included it in additional studies. In contrast, we 
find that rs10883866, located 5 kb 5’ of exon 2, has a strong and consistent 
effect in DLA experiments. The construct containing the common, non-risk 
variant conferred a 2-3 fold increase in expression over empty vector in all cell 
lines tested (in primary rat cortical neurons, the effect was more modest but in 
the same direction) and this effect was completely abrogated by the the risk 
variant. We conclude that rs10883866 is a causative variant that perturbs the 
regulatory function of a DNA element in this genomic location and that in these 
in vitro assays, the effect of the risk variant is to decrease expression. Similarly, 
rs60827755, located 1.5 kb 5’ of exon 2, also showed a consistent effect on 
expression in all cell types tested. In this case, however, the risk allele is 
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associated with an increased expression ranging from 0.25-2 fold over the 
empty vector and 2.5-6 fold over constructs with the non-risk variant (p= 10-4 - 
10-11). We conclude that rs60827755 is also a causative variant but with 
opposite effects on expression in these in vitro assays.  
A curious aspect of our results with rs10883866 and rs60827755 is that 
the minor alleles, which are both on the risk haplotype, direct expression of the 
reporter in opposite directions. In vivo, the effects of these variants will depend 
on the relative abundance of the trans-acting factors that bind these regions as 
well as the context beyond the 320 bp inserts in the test plasmids. 
 
SNPs in NRG3 correlated with alternate first exon use 
NRG3 undergoes complex alternative splicing with transcripts that 
originate from at least two alternative first exons, exons 1a and 1b.24 We 
hypothesized that the SNPs associated with the “delusion” factor, which are all 
located in the 5’ end of NRG3, might alter the relative abundance of transcripts 
that begin with exon 1a or exon 1b. To test this possibility, we asked if there 
was a correlation between the genotype of two variants (rs10748842, 
rs6087755) and the expression of different NRG3 transcripts in 2 brain regions 
(Figure 2-7).36  
After controlling for qPCR plate, age, sex, and post-mortem interval, 
colleagues in our laboratory found that carriers of the risk allele (C) at 
rs10748842 have decreased expression of transcripts containing exon 1b in the 
STG (p=0.026). The effect of the risk allele is highly significant when expression 
of transcripts initiating with 1b is adjusted for transcripts initiating with exon 
20 
 
1a (p=5.11 x 10-9).  Additionally, in the DLPFC, the risk allele is correlated with 
lower overall expression of transcripts containing exon 1b (p=1.9 x 10-7), as well 
as expression adjusted for expression of transcripts with exon 1a (p=4.7 x 10-8). 
The risk allele at rs60827755 (G) showed a similar correlation in the STG 
with decreased expression of transcripts with exon 1b overall (p=0.048) and 
when adjusted for expression of transcripts with exon 1a (p=1.9 x 10-7).  In the 
DLPFC, the risk allele is associated with decreased expression of transcripts 
with exon 1b (p=1.42 x 10-7) and decreased expression adjusted for exon 1a 
transcripts (p=6.0 x 10-8). This similarity is expected as the two SNPs are in 
strong LD (r2=0.92). 
From these data, we conclude that the effect of the delusion-associated 
variants involves the relative expression of various NRG3 transcripts. This 
suggests a transcript-specific mechanism, in which the risk variant of one SNP 
affects the utilization of alternative first exons.  
 It is important to clarify that these SNPs are associated with a patient’s 
score on the delusion factor, and not to risk of developing SZ per se. They are 
modifiers of the SZ phenotype, and, as such, may help to predict clinical 
presentation within the diagnosis of SZ. While they do not directly influence the 
risk or the severity of illness, they do increase susceptibility to delusions in SZ 
patients, suggesting the importance of NRG3 in the biological pathways of SZ. 
Further studies are required to study whether the same variants have similar 
effects in other clinically relevant phenotypic features such as functional 
impairment or response to specific antipsychotics in SZ. Further efforts are also 
needed to study whether these variants increase risk of developing more types 
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of delusions only in the context of SZ, or whether they influence the phenotype 
of other mental illnesses as well. 
Conclusion 
In summary, we show that alleles of intronic SNPs strongly associated 
with a delusion QT also modulate gene expression and alternative first exon 
utilization. The molecular mechanism by which the single base-pair changes 
exert their effect is unknown, although we surmise that the variants alter 
binding sites for transcription factors that interact indirectly with the 
promoter(s). The identity of the proteins that utilize these putative binding sites 
to control regulation of particular transcripts of NRG3, as well as the functional 
consequences of various splice forms in specific cells types, will shed light on 
the molecular pathways involved in delusions and psychiatric disease, as well 













Table 2-1: Microdeletion Frequency in Populations 








+/+ +/- -/-  
High delusion AJ SZ 73 8 146 65 8 0 5.8% 
Low delusion AJ SZ 67 0 134 67 0 0 0% 
AJ Control  642 36 1284 606 36 0 2.80% 
AJ SZ  641 34 1282 1248 34 0 2.65% 
Outbred SZ  346 0 692 346 0 0 0% 
AJ Bipolar  564 29 1128 536 27 1 2.57% 
 
Table2-1: Frequency of microdeletion in various population, including the 
extremes of the delusion score distribution in our AJ sample (high 
delusion AJ SZ and low delusion AJ SZ), a set of subjects with no 
psychiatric history (AJ Control), and the entire set of AJ SZ subjects 
regardless of their delusion score (AJ SZ). Additionally, SZ patients of a 
mixed background (Outbred SZ) and AJ subjects diagnosed with bipolar 
disorder are included (AJ Bipolar). For each group, the number of subjects 
tested, number of alleles tested, number of alleles bearing the deletion, 
number of subjects with each phenotype and the allelic frequency of the 
























rs10883862 83642101 T G 0.11 0/46 9/46 0.003 TRUE A 
rs10883866 83643639 C G 0.11 0/46 9/46 0.003 TRUE C 
rs60827755 83647518 A G 0.10 0/46 9/46 0.003 TRUE D 
rs10748842 83649739 T C 0.11 0/46 9/46 0.003 TRUE E 
rs7919976 83642034 G A 0.58 5/46 18/46 0.003 TRUE B 
rs74885547 83672780 T C 0.56 8/44 22/46 0.004 TRUE - 
rs10786760 83664575 C T 0.55 9/44 23/46 0.004 TRUE - 
rs1018484 83665670 T C 0.56 8/44 20/42 0.005 TRUE - 
rs10884019 83757021 G A 0.15 3/46 13/44 0.005 TRUE - 
rs11191757 83667910 G T 0.56 9/46 22/46 0.008 TRUE - 
rs10786762 83670102 G A 0.58 9/46 22/46 0.008 TRUE - 
rs10883921 83685802 A C 0.57 8/46 20/46 0.012 TRUE - 
rs7075126 83688159 A G 0.57 8/46 20/46 0.012 TRUE - 
rs10883898 83670126 C T 0.53 8/44 20/46 0.012 TRUE - 
rs9943299 83640808 A G 0.22 1/46 9/46 0.015 TRUE - 
rs6584400 83656526 G A 0.22 1/46 9/46 0.015 TRUE F 
rs3918483 83668440 C A 0.53 8/44 18/42 0.018 TRUE - 
 
Table 2-2: Results of our next-generation sequencing efforts. For each 
variant, we show the rs number, its position on chromosome 10 (using the 
hg19 reference genome), the reference and alternate alleles, the minor 
allele frequency, the number of alternate alleles out of the total alleles 
sequenced for both high and low delusion groups, the p-value, whether the 
alternate allele is on the deletion risk haplotype, and how we refer to this 
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allele in follow-up (if we followed-up). Variants are arranged by p-value, and 




Figure 2-1: Proposed Nomenclature for Exons of NRG3 
 
Figure 2-1: Gene Structure of NRG3.  A. Proposed nomenclature for 
validated exons in NRG3 (grey) and non-NRG3 transcripts (black). Exons 
and Introns are not to scale. B. Comparison with previous nomenclature.36  
1. Shortened versions (3bp) of this exon have been reported24 2. Shortened 







Figure 2-2: Region of the 5’ NRG3 region of interest 
 
Figure 2-2. A. Gel (0.75%) electrophoresis of amplicons shown in B from a 
subject heterozygous for a microdeletion (hg19: Chr10: 83 611 664 - 83 
A.













































































































































































































































































































































































































613 507). B. Quantity of variants observed in low- (black) and high- (red) 
delusion patients by amplicon. C. UCSC genome browser view of sequenced 
region in chromosome 10.  Tracks, from top to bottom, display genes, 
vertebrate conservation, histone marks (H3KMe1 and, separately, 
H3K4Me3), Multiz vertebrate alignment. D. UCSC genome browser view of 
region of NRG3 surrounding SNPs chosen for follow-up. Tracks, from top to 
bottom, display non-human Refseq genes, custom track marking regions 
tested in DLA assays, SNPs in the region, UCSC and Refseq genes, 
transcription factor binding sites, conservation amongst placental 












Figure 2-3: Dual-luciferase assays testing deleted region of NRG3  
 
Figure 2-3. Representative results from DLAs of the deleted region in 
A.HEK293 and B. HT22 cell lines. Each construct was tested in 6 








Figure 2-4. DLAs of short regions surrounding SNPs in A. HEK293 cells, B. 
Cultured rat primary cortical neurons, C. HT22 and D. Neuro-2A cells. 
Statistically significant results from two-tailed t-tests are shown. Each 
SNP (or pair of SNPs, in the case of rs7919976 and rs10883862) is 
represented by a different color; the first bar in each set represents major 
alleles and the second, minor alleles. Each construct was tested in six 














Figure 2-5: Schematic of 3-Primer Assay design 
 
Figure 2-5: Microdeletion genotyping by three-primer PCR assay using a 
single forward primer 5’ of the microdeletion and two reverse primers, one 
in the deleted region and one 3’ of the microdeletion.  PCR cycling 
conditions were: 94°C for 2 min, followed by 31 cycles of 30 sec at 94°C, 
61°C and 68°C. Amplifying from the deleted chromosome will preclude 
binding of the first reverse primer, so only a 249bp product will amplify 
from the second reverse primer and the common forward primer. The 
undeleted chromosome would theoretically amplify from both the reverse 
primers, but the second primer will generate a 2092bp fragment that is 
not seen due to the short extension time, so only a 406bp product from 
the primer within the deleted region is produced. Heterozygotes exhibit 




Figure 2-6: Inheritance of deletion in AJ families  
 
Figure 2-6: Representative sample of AJ family studies. Family ID and 
pedigree are shown above a 1.5% agarose gel electrophoresis of three-
primer assay amplicons. Controls for each genotype are shown at the far 
right. Pedigree symbols shaded white represent individuals with SZ, 
shaded symbols represent the presence or possible presence of other 
psychiatric disorders. Numbers in the symbols for the affected individuals 
represent the quartiles of the delusion score for that individual. The first 
quartile contains individuals with the highest delusion scores, and the 




Figure 2-7: Effects of rs1078842 on NRG3 alternative transcripts 
 
 
Figure 2-7. Log2 transformed expression of NRG3 transcripts initiating 
with Exon 1B grouped by genotype. A, samples from STG grouped by 
genotype for rs10748842. B, samples from STG grouped by genotype for 
rs60827755.  C, samples from DLPFC grouped by genotype for 
rs10748842. D, samples from DLPFC grouped by genotype for rs60827755.  
Note, expression is not relative to transcripts initiating with exon 1A, nor 
is it corrected for covariates such as age, sex, pmi, or qPCR plate.  
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Chapter 3 : Identification of transcription factors binding 
regulatory regions in NRG3 
 
Abstract 
Human NRG3 has been implicated in a “delusion” phenotype of 
schizophrenia (SZ). Three intronic SNPs in NRG3 have been shown to have 
regulatory potential, but no proteins are known to bind to those regions of the 
genome. To assess whether nuclear proteins bind to the 21-bp region centered 
around each of these SNPs, I conducted Electrophoretic Mobility Shift Assays 
(EMSAs) using cell types in which my previous dual luciferase reporter assays 
indicated the SNPs had regulatory effect. I found that all DNA probes generated 
a shifted band, but only rs10748842 and rs60827755 showed a noticeable 
allele-specific difference in shifted band pattern or intensity. Using a 
computational approach, we have identified candidate proteins potentially 
binding the DNA region including these 2 SNPs. We tested CNOT4 binding to 
rs60827755 by supershift and determined that CNOT4 binding to rs60827755 




Chapter 2 of this dissertation details the identification of SNPs in NRG3 
intronic regions that are associated with the delusion factor in SZ. 
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Furthermore, DLAs provided evidence for their regulatory function. In this 
chapter, I hypothesize that one or more regulatory DNA-binding proteins 
recognize and bind to the region of DNA including the SNP, and that protein’s or 
proteins’ ability to bind to the locus is affected by the allele of the SNP. The 
protein in question would be able to interact with other proteins to form an 
enhancer complex that may regulate temporal and regional expression of NRG3. 
In order to better elucidate the mechanism(s) whereby SNPs affect NRG3 
expression, and in turn, delusional manifestations in SZ, I sought to identify 
DNA-binding proteins that preferentially bound to regions including one of the 
alleles of the SNPs by testing hypotheses generated by in silico transcription 
factor predictions.    
 
Materials and Methods 
 
Electrophoretic Mobility Shift Assays (EMSAs) 
Nuclear extracts were collected from HEK-293, Neuro2A and HT22 cell 
lines using the Nuclear Extraction Kit (EMD Millipore Corporation, Billerica, 
MA) according to the manufacturer’s instructions and stored in single-use 
aliquots at -80°C. 
Probes were generated using 21bp oligonucleotides containing the SNP at 
the center position. Forward and reverse oligonucleotides for each allele of each 
SNP were treated with shrimp alkaline phosphatase (Affymetrix, Santa Clara, 
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CA) to remove end phosphate units (37°C for 1 hour, followed by a 15 minute 
inactivation step at 65°C), heated to 95°C and allowed to cool at room 
temperature for 1 hour in order to generate double-stranded oligonucleotides.  
To radiolabel the oligonucleotides, I incubated 2μl of the SAPed double-
stranded oligos with T4 Polynuclotide Kinase (New England Biolabs, Ipswich, 
MA) and 2μl of γ32P-ATP at 37°C for 1 hr. The product was purified using 
QuickClean Enzyme Removal resin (Clontech, Mountain View, CA) and Costar 
Spin-X centrifuge tube filter (0.22μm, Sigma-Aldrich, St. Louis, MO)column and 
mixed with 3μl of yeast tRNA. A half volume of ammonium acetate and 2 
volumes of cold 100% ethanol were added and the reaction was placed at -80°C 
overnight to precipitate, then spun for 15 minutes at room temperature. The 
pellet was washed with 70% ethanol, resuspended in DEPC-treated water, 
counted and diluted to either 4,000 or 2,000 cpm/μl. 
EMSAs were performed as described by Ye et al50, except that probes 
were made at 2000 cpm/μl, 5.2 ul of 3 mg/ml nuclear extract and precast 5% 
Mini-Protean TBE gels (Bio-Rad, Hercules, CA) were used. 
Competition EMSAs were performed in the same way as EMSAs, except 
that increasing amounts of unlabeled probe were added to the reactions (50nM, 
100nM, 200nM and 300nM unlabeled probe) at the same time as the labeled 
probes were added. 
 
 
In silico Prediction of Transcription Factor Binding Sites 
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 Proteins binding loci of interest were identified using a computational 
model trained on experimental enhancer data, as presented previously.51  
 
EMSA supershift assays 
 In order to test whether shifts seen in EMSAs were due at least in part by 
binding of the predicted protein (see “In silico prediction of transcription factor 
binding sites” above), EMSA supershift assays were conducted. Nuclear extracts 
and buffers were prepared in the same way as before, except that they did not 
contain DTT. After incubation of the reaction buffer, nuclear extract, poly(dI-dC) 
(Roche, Indianapolis, IN), BSA, and DEPC-treated water on ice for 10 minutes, 
CNOT4 antibodies (Catalog # 12561-1-AP, Proteintech, Chicago, IL and Catalog 
#ABIN485359, antibodies-online, Atlanta, GA) or Isotype control (Catalog 
#NB810-56910, Novus Biologicals, Littleton, CO) were added to appropriate 
lanes. Final isotype control concentration was matched to the final 
concentration of antibody. After a 2-hour incubation on ice, oligonucleotide 
probes were added, and the reaction was allowed to incubate on ice for 30 
minutes while the flushed gel was pre-run at 200 V. Samples were loaded and 
run as before.  
 




 In order to explore the protein-binding potential of the region including 
and surrounding our SNPs of interest, I performed a number of EMSA 
experiments. I chose to limit our study to rs60827755, rs10748842 and 
rs10883866 for reasons outlined in Chapter 2 (namely, consistent differences in 
expression between alleles when tested in DLAs). 
 
Nuclear Proteins Bind regions containing SNPs 
 First, I conducted a series of experiments to ascertain whether nuclear 
proteins bind the 21bp oligonucleotide centered around the SNP in question. 
The radiolabeled probe migrates to the bottom of the gel if unbound. If nuclear 
protein(s) bind the oligonucleotide, the complex exhibits retarded migration 
which would appear as a band or bands above the free probe.  
 EMSA competition experiments were also carried out in order to compare 
the binding strength of the protein-DNA interactions between alleles of the 
same SNP. For these experiments, equal amounts of radiolabeled probe are 
competed against increasing amounts of unlabeled probe of the same allele and, 
separately, of the opposite allele. 
rs10883866: Our EMSA testing SNP rs10883866 showed a noticeable 
shift only in lanes with both radiolabeled probe and nuclear extract (See Figure 
3-1). When I used HEK293 nuclear extract, I could see no clear difference in the 
pattern and intensity of the bands generated by the two alleles of rs10883866 
(Figure 3-1, lanes 3 and 8). HT22 nuclear extract generated a slightly less-
intense band when the radiolabeled probe contained the G (risk) allele of the 
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SNP, although the bands were of a different size than those seen with HEK293 
nuclear extract (Figure 3-1, lanes 4 and 9). EMSA competition assays revealed 
no discernible difference in protein binding strength between alleles (Figure 3-
2). 
I therefore conclude that the 21bp region including rs10883866 appears 
to bind nuclear proteins. Since there is a difference in the banding pattern 
generated by the nuclear extracts from the two cell types, the identity of the 
proteins may be different, or they are orthologs but the divergence between the 
two species (mouse and human) generates different-sized proteins, or they are 
orthologs whose splicing patterns differ in the tissues (kidney versus 
hippocampus). We furthermore conclude that in HEK293 experiments, we have 
no evidence to support our hypothesis that the alleles of the SNP affect the 
DNA-protein binding.  
rs10748842: SNP rs10748842, on the other hand, shows marked 
differences between the banding pattern generated by the two alleles of the SNP 
(Figure 3-3: allele C, lanes 3 and 4; allele T lanes 8 and 9). In experiments 
including HEK293 nuclear extract, the C (risk) allele generates only one band, 
which appears to be composed of at least two separate bands that overlap 
(Figure 3-3, lane 3). The T (protective) allele generates what appears to be the 
same band, but also generates two higher and one lower band (Figure 3-3, lane 
8). Therefore, it appears that some protein or proteins bind this region 
regardless of the genotype at the SNP, but others bind imperceptively, if at all, 
to the C (risk) allele. When the experiment was performed using HT22 rather 
than HEK293 nuclear extract, one clear single band appears only with the C 
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(risk) allele (Figure 3-3, lane 4). A broader band most likely consisting of several 
overlapping bands appears regardless of genotype, but appears stronger with 
the C (risk) genotype (Figure 3-3, lanes 4 and 9). I conclude that the DNA 
sequence in question appears to bind to one or more nuclear proteins. One 
allele generates bands not seen with the other, but the allele resulting in more 
bands are different in different cell types (C in HT22, T in HEK293), suggesting 
that the effects of this SNP may be cell-type or species-specific. 
 Furthermore, EMSA competition assays performed in HEK293 cells 
(Figure 3-4) demonstrate that the shifted bands diminish in intensity at lower 
concentrations of C allele compared to T allele. This suggests that the C allele is 
binding most strongly to the protein or proteins generating the band. It is also 
interesting to note that as the intensity of the strongest band decreases with 
increasing amounts of cold T allele probe, another, higher, more diffuse band 
generated by the labeled C allele probe-protein complex  seems to increase in 
strength proportional to the main band at the same time that it appears to 
migrate further through the gel. This suggests that the C allele may have the 
ability to bind to a family of proteins of varying molecular weights, with slightly 
different binding affinities.  
rs60827755: EMSAs with SNP rs60827755 and HEK293 nuclear extract 
generate a doublet which appears more intense when binding the A (protective) 
allele, as evidenced by the comparisons of the band in the lanes with HEK 
nuclear extract (Figure 3-5, lanes 3 and 8). HT22 nuclear extract does not 
generate discernible bands (Figure 3-5, lanes 4 and 9). This may mean that the 
protein-probe complex is beneath the limit of detection, or that the protein 
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mediating the effect in the dual-luciferase reporter assays is unable to bind to 
the DNA probe under the conditions of the assay.  
Competition assays performed with HEK nuclear extract (Figure 3-6) 
demonstrate that the addition of unlabeled oligonucleotide with the A allele 
causes all bands to diminish in intensity at a lower concentration than 
oligonucleotide with the G allele. This means that the A (protective) allele 
appears to bind more strongly than the G (risk) allele to the proteins in 
question.  
  
CNOT4 as a possible binding protein 
 In collaboration with Dr. Michael Beer, I used a bioinformatics approach 
to determine the effect each SNP was expected to have on any protein binding 
sites overlapping its locus.  
rs10883866: The computational analysis predicted that rs10883866 was 
not expected to change any binding sites. We find this in accordance with our 
EMSA results, which showed minimal difference in the pattern of shifted bands 
generated by the two alleles, as well as indiscernible differences in the 
competition assays testing relative binding affinity. 
Since both the in silico and the in vitro approaches are in agreement, I 
conclude that rs10883866 does not exhibit differential binding affinity to its 
protein binding partner. The effects seen in the DLAs presented in the previous 
chapter suggest that the SNP has some regulatory effect, but we postulate that 
the mechanism does not include direct protein binding at the DNA level. 
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rs10748842: Kao et al.36 have previously reported in silico experimental 
results suggesting that rs10748842 lies in a homeodomain binding motif to 
which a number of protein domains, Hox, LIM, POU and PAX among them, 
bind. The SNP alters this motif, and so the alleles expected to have differential 
binding ability. Our computational approach supports this prediction, 
increasing our confidence in its predictive abilities. However, because of the 
sheer number of proteins predicted to bind this site, we chose not to approach 
with EMSA supershift studies using a series of antibodies. Rather, we will wait 
for the results of a protein microarray experiment which will interrogate 
differential binding ability for many transcription factors simultaneously. 
rs60827755: Our computational analysis predicted that rs60827755 
could alter the binding site of a protein known as CNOT4. This protein is a 
member of the Ccr4-Not complex, a regulator of transcription, particularly by 
RNA Polymerase II52. In addition to its role as a transcription factor complex, 
mRNA metabolism, ubiquitin ligase and mRNA turnover functions have been 
assigned to the Ccr4-Not complex53. CNOT4 has a RING finger domain, which 
suggests an ability to bind DNA directly54. 
In order to test whether the CNOT4 protein binds the 21-bp probe 
around rs60827755, I conducted supershift assays using antibodies against 
CNOT4. If formed, the protein-DNA probe-antibody complex should generate a 
“supershift” that is not observed in the absence of antibody, or when the 
antibody is replaced by an isotype control.  
I observed a shift (Figure 3-7, lanes 3 and 8) when the reaction contained 
HEK293 nuclear extract as well as labeled probe. However, addition of the 
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antibody did not generate an additional band. It should be noted, however, that 
there is a marked reduction in the intensity of the shifted band in the lanes 
containing antibody, nuclear extract and labeled probe (Figure 3-7, lanes 4 and 
8). This reduction is not seen with isotype control instead of antibody (Figure 3-
7, lanes 5 and 9). These data suggest that it is possible that antibody binding to 
CNOT4 is causing a reduction of signal by preventing the CNOT4-antibody-DNA 
probe from migrating through the gel. Alternatively, the antibody may be 
impeding protein-DNA binding, but in that scenario, I would expect the 
unlabeled probe signal to be significantly greater in lanes with antibody (Figure 
3-7, lanes 4 and 8) than in lanes without it (Figure 3-7, lanes 3 and 7), which I 
do not observe.  
I performed the same experiment using HT22 nuclear extract but found 
only slight differences between lanes with and without antibody (Figure 3-8, 
lanes 3, 5, 8 and 10 compared to lanes 4 and 9). As with HEK, no supershifted 
band was observed.  
When I repeated this experiment with Neuro 2A nuclear extract, I 
observed that lanes without the CNOT4 antibody exhibited the same banding 
pattern as lanes with CNOT4 antibody (Figure 3-9, lanes 3, 5, 8 and 10 
compared to lanes 4 and 9), suggesting no supershift band occurred. There was 
a reduction in signal intensity of the principal shifted band when antibody was 
added (Figure 3-9, lanes 4 and 9), but a second band (observed also in lanes 
without antibody) remained as intense as control lanes (Figure 3-9, lanes 3,5,8 
and 10). I therefore cannot conclusively show CNOT4 binding to our DNA region 
of interest, but neither can I dismiss CNOT4 as being at least partially 
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responsible for the shifted band observed in EMSAs with rs60827755 and 
possibly involved in mediating the effect of the SNP on regulation of NRG3. In 
order to confirm or refute involvement of CNOT4 with regulation of NRG3, 
further experiments are warranted, including a protein microarray experiment 
currently underway. 
    
 
Conclusions 
I have shown that the 21-bp regions containing our 3 SNPs of interest 
are capable of binding proteins in at least one of the cell types tested. I observe 
no significant differences in protein binding intensities or patterns for 
rs10883866, in accordance with our computational predictions. Because of the 
apparently limited effect of the SNP on differential binding, I chose not to 
pursue this SNP in our supershift experiments.  
 My data also show that rs10748842 is responsible for a difference in the 
binding pattern and intensity in our EMSAs. The multiple bands seen, 
especially in HEK293 cells, agree with computational predictions performed by 
us and others36, suggesting multiple proteins are capable of binding the region 
containing the SNP. Because of the daunting number of putative binding 
proteins, I chose not to pursue this approach by supershift.   
 I found rs60827755 exhibited weak but specific shifting in the presence 
of HEK293 nuclear extract but bands were below the limit of detection with 
HT22 nuclear proteins. I notice an allele-specific difference in band intensity. 
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The experiments described in the latter part of this chapter suggest that there 
may be an involvement of the CNOT4 protein in the formation of the complex 
that appears as a shifted band in the EMSAs. However, my experiments were 
unable to conclusively prove or disprove its ability to bind our region of interest. 




Figure 3-1: rs10883866 EMSA using HEK293 and HT22 nuclear extracts 
 
Figure 3-1. Electrophoretic Mobility Shift (EMSA). Radiolabeled probes 
containing either allele of rs10883866 were tested in the presence and absence 
of either HEK293 or HT22 nuclear extracts.  
47 
 
Figure 3-2:10883866 EMSA competition with alternate allele using 
HEK293 nuclear extract 
 
Figure 3-2. Competition Electrophoretic Mobility Shift (EMSA). 
Radiolabeled probes containing one allele of rs10883866 were incubated 
with HEK293 nuclear extract in the presence of various amounts of 








Figure 3-3: rs10748842 EMSA using HEK293 and HT22 nuclear extracts 
Figure 3-3. Electrophoretic Mobility Shift (EMSA). Radiolabeled probes 
containing either allele of rs10748842 were tested in the presence and 











Figure 3-4: rs10748842 EMSA competition with alternate allele using 
HEK293 nuclear extract 
 
Figure 3-4. Competition Electrophoretic Mobility Shift (EMSA). 
Radiolabeled probes containing one allele of rs10748842 were incubated 
with HEK293 nuclear extract in the presence of various amounts of 









Figure 3-5: EMSA with HEK293 and HT22 nuclear extracts 
 Figure 3-5. Electrophoretic Mobility Shift (EMSA). Radiolabeled probes 
containing either allele of rs60827755 were tested in the presence and 












Figure 3-6: EMSA competition with alternate allele using HEK293 nuclear 
extract 
 Figure 3-6. Competition Electrophoretic Mobility Shift (EMSA). 
Radiolabeled probes containing one allele of rs60827755 were incubated 
with HEK293 nuclear extract in the presence of various amounts of 











Figure 3-7: rs60827755 EMSA supershift with HEK293 nuclear extract 
 
Figure 3-7. Electrophoretic Mobility Shift (EMSA) Supershift. Radiolabeled 
probes containing one allele of rs60827755 were incubated with HEK293 
nuclear extract in the presence of anti-CNOT4 antibody (lanes 4 and 8), 
isotype control (lanes 5 and 9), or both antibody and an excess of 









Figure 3-8: rs 60827755 EMSA supershift with HT22 nuclear extract 
 
Figure 3-8. Electrophoretic Mobility Shift (EMSA) Supershift. Radiolabeled 
probes containing one allele of rs60827755 were incubated with HT22 
nuclear extract in the presence of anti-CNOT4 antibody (lanes 4 and 8), 
isotype control (lanes 5 and 9), or both antibody and an excess of 









Figure 3-9: rs 60827755 EMSA supershift with Neuro2A nuclear extract 
 
Figure 3-9. Electrophoretic Mobility Shift (EMSA) Supershift. Radiolabeled 
probes containing one allele of rs60827755 were incubated with Neuro2A 
nuclear extract in the presence of anti-CNOT4 antibody (lanes 4 and 9), 
isotype control (lanes 5 and 10), or both antibody and an excess of 




Chapter 4 : Characterization of a Nrg3 knockout mouse 
 
Abstract 
Stimulated by our data implicating variation in NRG3 either contributes 
for risk for schizophrenia or influences the phenotypic manifestations of 
schizophrenia (SZ), I tested a murine Nrg3 constitutive knockout mouse 
developed by our laboratory for both behavioral and neuronal phenotypes 
relevant to the NRG/ErbB4 pathway. A battery of behavioral tests revealed a 
pervasive hyperactivity phenotype, even at baseline. Additional findings include 
decreased anxiety, pre-pulse inhibition and startle response deficits, fear 
and/or emotional- based learning or memory deficits, and perturbed working 
memory. At the neuronal level, I tested the hypothesis that Nrg3-/- mice may 
have GABAergic interneuron migration deficits by immunofluorescent staining 
of brain sections from mice injected with EdU prior to neuronal migration. I 
conclude that there is no deficit of GABAergic interneurons in the cortical areas 
assessed in Nrg3-/- brains. However, a deficit of GABAergic interneuron 
precursors during development and depletion of PV+ cells in postnatal brains 









In this chapter, I focus on experiments aimed at characterizing a Nrg3 
knockout mouse developed in our laboratory. The targeted disruption of Nrg3 
was designed so that exon 2 (present in all four known transcripts of murine 
Nrg3) would be eliminated.  
My first research question focuses on the behavioral phenotype of this 
mouse strain. Although SZ is a human-specific disease, genetic (and other 
drug-induced or surgical) mouse models can display certain facets or 
endophenotypes of human SZ such as social withdrawal or cognitive deficits. It 
is by studying SZ in a “piecemeal” fashion, mouse models allow investigators to 
perform studies that would be impossible, unethical or impractical in 
humans.55-57 Just as humans with SZ rarely manifest all known symptoms of 
SZ, even ideal mouse models likely will only manifest some behavioral changes 
that may be related to SZ.58  
 Positive symptoms of SZ (including delusions) have classically been 
tested in mouse models using pre-pulse inhibition (PPI) and locomotor 
hyperactivity. Locomotor hyperactivity (particularly as a proxy for psychotic 
agitation) has been used to test for dopaminergic changes, especially after 
exposure to amphetamines. N-methyl-D-aspartate (NMDA) receptor antagonists 




 The startle response is a plastic, unconditioned reflex characteristic of 
vertebrates, but impaired in subjects with SZ (as well as other psychiatric 
diseases) and many mouse models of psychiatric disease. Impaired PPI is 
generally considered to reflect defects in the inhibition of neural circuits critical 
for sensorimotor gating. Deficient sensorimotor gating can result in cognitive 
fragmentation and sensory overload, with psychotic and cognitive implications. 
PPI can model a deficiency in glutamatergic signaling or an increase in 
dopaminergic activity.59  
In addition to the literature supporting a PPI deficit in SZ, PPI testing for 
animal models of psychiatric disease is a choice test because both humans and 
mice are tested in a similar fashion.60  
My second research question focuses on the cellular phenotype of 
knocking out murine Nrg3. In 2012, Li et al.30 reported that NRG3 and NRG1 
were key chemorepellant signals necessary to guide GABAergic interneurons 
through their migration via the tangential migratory route. This route leads 
from the medial ganglionic eminence (MGE), where the interneurons are 
generated, to their final location in the cortex. The findings of Li et al. differed 
from previous work suggesting chemoattractant properties of NRGs that allow 
migration of interneurons, such as Flames et al.61 However, the effect of 
abolishing or diminishing NRG3 in the developing brain has not been tested in 





Materials and Methods 
 
Generation of a Nrg3 Knockout (KO) Mouse 
A Nrg3 knockout mouse previously generated in the Valle lab by Lilei 
Zhang and Pei-lung Chen was utilized in all experiments in this chapter. Exon 2 
(GRCm38/mm10 Chr14:39,011,969-39,012,099) was targeted for deletion 
using a Neomycin cassette flanked by both FRT and LoxP sites (see Figure 4-1), 
as well as genomic regions flanking Exon 2. Successful homologous 
recombination was tested by Southern Blot and PCR. Chimeric mice were 
generated by the Johns Hopkins Transgenic Core Laboratory and bred to mice 
carrying a constitutive Cre cassette. Congenic mice were generated by 
backcrossing a minimum of 10 times to C57BL/6 mice (Jackson Laboratory, 
Bar Harbor, Maine).  
 
Northern Blot 
 Northern blots were prepared as described previously62,63 with 2 ug poly-
A RNA extracted from murine brains at ages E14, E16, E18, P1, P3, and P42. 
 
Behavioral Studies 
 For acoustic startle response experiments64, 9-10-week-old mice were 
tested once each. Mice with startle responses below 100 were excluded, for a 
total of 6 mixed-background Nrg3+/+ males, 6 mixed-background Nrg3-/- males, 
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9 backcrossed Nrg3+/+ males, 11 backcrossed Nrg3-/- males, 4 mixed-
background Nrg3+/+ females, 2 mixed-background Nrg3-/- females, 15 
backcrossed Nrg3+/+ females and 14 backcrossed Nrg3-/- females.   
 Y-maze experiments65 utilized 5 Nrg3-/- females, 7 Nrg3+/+ females, 2 
Nrg3-/- males and 7 Nrg3+/+ males, all from a mixed background and between 
10-12 weeks of age.  
 24-hour circadian rhythm tests64 used mixed-background mice 10-12 
weeks of age (6 male Nrg3-/-, 6 male Nrg3+/+, 5 female Nrg3-/-, 5 female Nrg3+/+). 
The dark period persisted from 8pm to 8am. 
 Fear conditioning was performed as described previously66 using 9 male 
mice of each genotype. If data failed normality testing, we calculated least 
squares means for group by time interaction. 
 Open field tests were described previously67 and were performed with and 
without MK-801 on 6-month old mice. Mice were tested only once, as follows: 
30 minute observation period, saline injection, 30 minute observation period, 
MK801 (0.3 mg/kg) injection, 2 hour observation. 14 mixed-strain male mice of 
each genotype were tested. Data that failed a normality test was normalized by 
obtaining least square means.  
 For hot plate tests68, mice placed on a Columbus Instruments 
(Columbus, OH) hot plate analgesia meter set at 55°C and the time to paw-lick 
response was recorded in seconds. We used 6 Nrg3+/+ males, 8 Nrg3+/+ females, 
6 Nrg3-/- males and 5 Nrg3-/- females of mixed-background, as well as 3 Nrg3+/+ 
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males, 5 Nrg3+/+ females, 3 Nrg3-/- males and 4 Nrg3-/- females in a C57BL/6J 
background. For each mouse, 2 trials were conducted and averaged.  
  Plus-maze tests64 were performed on 3-month-old mixed-background 
mice (5 female Nrg3-/-, 5 female Nrg3+/+, 6 male Nrg3-/-, 6 male Nrg3+/+) In 
addition to time spent on the closed and open arms, the following data was 
collected: number of fecal boli produced, urination (binary), number of times 
mice leaned over the edge, number of peeks, rearing activity, cleaning activity 
and stretching. Outliers (3 female Nrg3+/+, one female Nrg3-/-, one male Nrg3-/- 
and one male Nrg3+/+ inactive mice) were eliminated from statistical analysis.  
 
EdU Migration Assays 
To track the migration of cells in the developing brain, we mated Nrg3+/- 
heterozygotes to generate a timed pregnancy (E0 designated as midnight on the 
night of mating). At E12.5, the dam was given a peritoneal injection of 50 ug 
EdU (Life Technologies, Carlsbad, CA) per g of mouse in a total volume of 500 μl 
of sterile PBS. Dam and/or offspring were sacrificed at several timepoints 
(E12.5 1 hour after injection, E17.5, P0, P27 and P61). A cardiac perfusion with 
PBS and 4% PFA was performed for P27 and P61 mice prior to removal of the 
brain. For P0, E17.5 and E12.5, the dam was anesthetized and sacrificed, and 
the pups’ brains (E17.5, P0) or heads (E12.5) harvested. All brains were placed 
in a 4% PFA solution overnight at 4°C overnight. P61 and P27 brains were then 
placed in PBS and sectioned using a vibratome set to collect 50-micron coronal 
sections. All others were placed in 15% and then 30% sucrose gradients until 
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sunk, then embedded in OCT and sectioned using a cryostat. Coronal sections 
were collected at 14 microns for E12.7 brains and ~35 microns for all others.  
 
Immunohistochemistry 
For free-floating vibratome sections (ages P27 and P61), every 12th free-
floating section was collected and stained starting four sections from the first 
section where the hemispheres were joined. For cryostat sections, comparable 
sections were selected without regards to genotype and stained. All steps were 
performed at room temperature unless otherwise indicated. Slides or sections 
were rinsed in PBS for 5 minutes shaking, washed three times for 5 minutes 
each in PBT (0.2% Triton-X100 in PBS), then blocked in a humid box with 10% 
normal donkey serum in PBT. A Pap-pen (Sigma-Aldrich, St. Louis, MO) was 
used to delineate sections in slides. Primary antibodies were diluted in 10% 
normal donkey serum in PBT to stain overnight at 4°C in the dark. Parafilm 
coverslips were fashioned for slides. After allowing sections and slides to warm 
to room temperature, coverslips were removed and the sections or slides 
washed 3 times with PBT for 5 minutes each. AlexaFluor 568 and/or 680 (Life 
Technologies, Carlsbad, CA) were used at a dilution of 1:500 in 1% normal 
donkey serum in PBT for 2 hours in a humid, dark box. Slides and sections 
were washed in the dark three times for 5 minutes each with PBT, and the EdU 
Click-IT AlexaFluor 488 (Life Technologies, Carlsbad, CA) reaction performed 
according to manufacturer’s instructions for 30 minutes. Slides and sections 
were washed as before but with PBS, counterstained with DAPI (1:10,000) for 5 
minutes in the dark, and washed twice for 3 minutes each in PBS. Free-floating 
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sections were arranged on slide, and all slides mounted with PermaFluor 
Aqueous Mounting Media (Thermo Scientific, Waltham, MA) and left to dry in 
the dark.   
Primary antibodies for all embryonic stages and P0: Anti-Lhx6 (Novus 
Biologicals, Littleton, CO) and Anti-TTF1 (also known as Nkx2.1) (Upstate Cell 
Signaling Solutions, Lake Placid, NY) were used at a 1:500 dilution For P27 and 
P61, Anti-Parvalbumin antibody (Swant PV 25, Switzerland) was used at a 
1:2,000 dilution. 
Slides were imaged using a Zeiss fluorescent microscope, For P27 and 
P61, the third, fifth and seventh section (rostral to caudal) were imaged at 200x 
magnification (20x objective). For P0 and E18, sections imaged corresponded to 
coronal sections at ~1.3, -0.94, and -2.9 mm from bregma. For adolescent and 
adult brains, the sections corresponded to ~1.2, -0.9, and -1.9 mm from 
bregma.  
Images were analyzed with the help of either Adobe Photoshop (San Jose, 
CA, for manual counting and photomerging of multiple images) or Volocity 
(PerkinElmer, Waltham, MA, for automated counting). Experimenters were 
blind to genotype while counting. For each image, the number (or intersecting 
pixels) of cells positive for both Parvalbumin and EdU in the view was counted, 
as well as the number (or total pixels) of Parvalbumin positive cells, and the 





Results and Conclusions  
 
Generation of the NRG3 Knockout Mouse 
Efficiency of the knockout mouse was tested by Northern Blot comparing 
Nrg3-/-, Nrg3+/-, and Nrg3-/- littermates. As seen in Figure 4-2, the knockout 
animals expressed greatly reduced levels of NRG3 mRNA at every timepoint 
tested. The mRNA levels of other possible components of the Neuregulin system, 
NRG1 and ErbB4, however, did not vary according to Nrg3 genotype.  
 
Prepulse Inhibition and Startle Response 
In order to study the effect that an absence or decrease in NRG3 levels 
may have on a mouse’s PPI phenotype, we tested wildtype and homozygous 
knockout littermates from heterozygote x heterozygote matings. Two different 
genetic backgrounds were tested: the original transgenic strain, which is a 
mixture of 129 and C57BL/6J strains, as well as transgenic mice backcrossed 
(at least 10 generations) to the C57BL/6J strain.  
As expected,69 genetic background had a significant effect on PPI, so we 
focused our analyses on within-strain comparisons.  
As seen in Figure 4-3A, mixed-strain male Nrg3+/+ mice displayed a more 
modest startle response than their Nrg3-/- littermates. The difference reached 
statistical significance (two way repeated measures ANOVA p=0.049). The 
difference between Nrg3+/+ and Nrg3-/- males was not evident in the backcrossed 
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mice, perhaps due to an unknown modifier that masks the differences between 
Nrg3+/+ and Nrg3-/- in the backcrossed strains but not in the mixed-background. 
This could be discerned by backcrossing the mixed-background mice to a 129 
background to compare their PPI to backcrossed C57BL/6J.  
Females (Figure 4-3B) did not exhibit a discernible difference between 
Nrg3+/+ and Nrg3-/- in either strain, although it should be noted that the number 
of subjects for the mixed-background strain was small after eliminating 
individuals with startle responses below 100. 
The percent of prepulse inhibition (%PPI) was calculated at 5 different 
prepulses. In the mixed-strain male mice (see Figure 4-3C), the Nrg3-/-  mice 
exhibited diminished %PPI at all prepulses (two way repeated measures ANOVA 
p=0.073).  As with the startle response, the Nrg3-/- backcrossed males did not 
significantly differ from the backcrossed controls (p=0.543), nor did the female 
Nrg3+/+ and Nrg3-/- mice of either background differ from each other. 
Therefore, we conclude that there is a trend towards reduced %PPI and 
increased startle response in Nrg3-/- males versus Nrg3+/+ males, but this 
phenotype is only evident in a mixed-strain background. Testing more mice, 
both in the mixed-strain background and in a 129 background, may help 
support these observations. 
 
Fear conditioning 
The fear conditioning paradigm posits that an animal that learns to 
associate a stimulus (in this case, a tone) to an adverse event (shock) will 
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exhibit freezing behavior when the stimulus is sensed.  Although the freezing 
behavior is mediated by the amygdala, the hippocampus is responsible for 
storing the conjunctive representation (in other words, the memory of the 
association of the stimulus with the adverse event) in the cortex70. At the 
circuitry level, deficits in communication between the three brain regions may 
be expected to result in poorer performance in the fear conditioning test. 
We trained the mice to associate a novel tone with a shock on Day 1, 
after which we desensitized them to the chamber on Day 2 (no shock, no tone). 
On Day 3, we tested response to a tone (no shock), measuring the mice’s ability 
to create and remember the association between the shock and the tone.  
As seen in Figure 4-4, Nrg3-/- males show a decrease in freezing behavior 
compared to Nrg3+/+, even at baseline. The difference is more pronounced after 
the tone and shock (which persists from minute 2 to 2.5) during the first day of 
testing. During the second day, the Nrg3-/- mice are again much more active 
(less freezing behavior) than the Nrg3+/+ mice. It should be noted, however, that 
both genotypes show an increase in freezing behavior in Day 2 compared to 
their performance on Day 1. On the third day of testing, freezing behavior 
during the first minute (prior to tone) is comparable to freezing behavior 
exhibited in Day 2. However, upon hearing the tone, the Nrg3+/+ mice increase 
their freezing behavior but the Nrg3-/- mice do not. Only after the tone ends does 
the freezing behavior of the Nrg3-/- mice increase.  
On  Day 1 and Day 3, Nrg3-/- mice had a significantly reduced average 
freezing behavior across the five minutes of the test compared to Nrg3+/+ mice 
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(two way repeated measures ANOVA p<0.001 and p=0.003, respectively). Day 2, 
when the mice were allowed to habituate to the arena, was not (p=0.387).  
These may indicate that the Nrg3-/- mice failed to correctly form, store 
and/or recall the association between the tone and the shock. An alternative 
explanation is that the Nrg3-/- mice are hyperactive compared to Nrg3+/+. If so, 
they would be expected to exhibit less freezing behavior regardless of context or 
stimuli. It is important to note that a hyperactivity phenotype is likely to deeply 
confound this test. Additionally, if the Nrg3-/- mice have sensory deficits such 
that the shock was less painful to them, this would also prove to be a 
confounding factor in this analysis. For this reason, we tested mice to explore 
hyperlocomotion and nociception.    
 
Hot Plate Test 
The hot plate test is a measure of pain sensation (nociception) and 
important in understanding whether altered nociception may be a confounding 
factor in other behavioral tests. For each strain, we saw no differences between 
sexes or between genotypes (Figure 4-5, 2-tailed t-tests ranged between 0.2 and 
0.7).  Thus, we conclude that for each strain, there is no differential sensitivity 
to pain (at least thermal pain).  
 
24-hour circadian rhythm 
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24-hour circadian rhythm tests were performed in order to explore 
spontaneous locomotor differences between Nrg3+/+ and Nrg3-/- mice. As seen in 
Figure 4-6, the KO mice of both sexes exhibit higher locomotive activity, but the 
results do not reach statistical significance (2-factor ANOVA with replication, 
males, p=0.208; female, p=0.085). Nonetheless, because of its importance as a 




The open field paradigm assesses a number of behaviors: anxiety 
(although it should be considered only an initial screen), exploration of novel 
environments (first 5 minutes), habituation, and locomotor actitivy both at 
baseline and, in our case, under the influence of MK-801.71   
To study the baseline behavior of the mice, we compared the activity of 
the mice during the first 30 minutes (prior to any injections). The Nrg3-/- mice 
spent a greater percentage of their time exploring the center of the field (Figure 
4-7 E), which mice generally avoid due to thigmotaxis. However, the difference 
was not statistically significant (2-tailed t-test p=0.18). During this same period, 
we compared the peripheral, central and total (peripheral plus central) activity 
of the mice (Figure 4-7F) and found that the central and total activity measures 
were significantly different between genotypes (two way repeated measures 
ANOVA p=0.037 and p=0.022, respectively). The data reveal that the difference 
seen in total activity is driven by the difference in central activity, with the Nrg3-
/- mouse exploring the center more than the control mice. Therefore, it appears 
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that Nrg3-/- mice are more likely to explore the center and may experience less 
anxiety in response to this stress. Open Field, however, is not a test designed to 
measure anxiety, so other tests (including the elevated plus maze) must be 
conducted in order to claim a difference in anxiety. 
 In order to explore novel exploratory drive, we compared the total activity 
in the first five minutes with the total activity during minutes 25-30. We found 
that in both intervals, the Nrg3-/- males were more active than the control males 
(interval 0-5: 2-tailed t-test p=0.073; interval 25-30: p=0.032, see Figure 4-7. 
The difference between activity during the two intervals for mice of a given 
genotype was not significant (2-tailed t-test p=0.385), nor was the difference in 
percentage of time spent in the center (p=0.861). Thus, we conclude that the 
Nrg3-/- mice appear to be more active than the Nrg3+/+, but this is not a direct 
effect of novelty since the change in exploratory behavior was not significantly 
different between genotypes. 
 Additionally, we note that after exposure to MK-801, all mice experience 
hyperlocomotion, as expected (Figure 4-7A). However, the Nrg3-/- mice appear to 
be more sensitive to this drug than their control littermates. The results are 
nearly significant (two way repeated measure ANOVA p=0.055). Given the 
confounding factor of genotype-dependent baseline activity, we computed the 
corrected average difference of the least square means for each genotype at each 
timepoint (Figure 4-8) and compared the differences between different periods. 
A comparison of the first 30 minutes (baseline) to the entire 2 hours after MK-
801 exposure (overall effect) reveals that there is a statistically-significant 
difference (p=0.037) not completely accounted for by genotype-specific baseline 
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activity differences (Figure 4-8A). If, however, instead of comparing the initial 30 
minutes of baseline activity to the entire two hours of MK-801 exposure, we 
compare the 30 minutes of baseline to the first 40 minutes of MK-801 exposure 
(during which MK-801 induced activity is still increasing), we find that the 
differences are not statistically significant (p=0.52, Figure 4-8B). Comparison of 
the 30 minutes of baseline with the last 80 minutes of MK-801 exposure (Figure 
4-8C, the period during which MK-801 induced activity begins to wane) reveals 
that it is the late effects of MK-801 that are driving the difference between 
genotypes (p=0.0012).  We therefore conclude that there is a difference in the 
response of the Nrg3-/- mice to MK-801, that this difference is not completely 
explained by baseline differences in activity, and that it is driven by the late 
effects of MK-801.   
 
Elevated Plus Maze 
Elevated plus maze experiments are designed to measure anxiety in 
mice. Anxious mice will prefer to remain in the closed arms, whereas less 
anxious mice will explore the open arms. The percentage of time the male Nrg3-
/- mice spent in the open arm was more than twice as much as the Nrg3+/+ 
males (19.8% for Nrg3-/-, 9.8% for Nrg3+/+), but the differences did not reach 
statistical significance for any group (Figure 4-9).  Therefore, we conclude that 
the male Nrg3-/- mice trend towards decreased anxiety. As before, this would 
support previously-described evidence for a hyperactive phenotype in the Nrg3-/- 
males. However, if Nrg3 has unknown consequences on motor ability, urge to 





Y-maze experiments are commonly used to test spatial working memory 
in rodents, taking advantage of their tendency to explore novel environments. 
Mice were scored on the number and type of alterations between the three 
arms, with “triad” alterations consisting of entering each arm in turn and “non-
triad” alterations consisting of any pattern of entry into the arms that does not 
consist of entering each of the three arms once before repeating an arm. 
Although the number of non-triad alterations were similar in males of either 
genotype, the Nrg3-/- males had a higher number of triad alterations and a 
higher number of overall alterations on average, but neither of those 
comparisons reached statistical significance (2-tailed t-test: total p=0.0866, 
triads p=0.1311, nontriads p=0.9714) (see Figure 4-10) Females, however, 
exhibited relatively similar numbers of triad alterations (2-tailed t-test 
p=0.8923), but Nrg3-/- females had close to twice the number of non-triad 
alterations (2-tailed t-test p=0.00945). The total number of alterations did not 
reach statistical significance (2-tailed t-test p=0.4172).  
 As seen in Figure 4-10, the Nrg3+/+ mice of both sexes, as well as the 
Nrg3-/- females, tended to spend more time exploring the arm that had been 
previously blocked, compared to the arm that had never been blocked, although 
only the comparison between time in previously-blocked arm versus time in 
open arm in Nrg3+/+ females reached statistical significance (2-tailed t-test 
p=0.03359). Nrg3-/- males averaged more time in the open arm, but it should be 
noted that for this experiment, the number of male Nrg3-/- mice was too small to 
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draw conclusions. Further experiments with greater number of mice are 
underway at the time of writing. 
   
 
Gross Neuroanatomy of Nrg3-/- mouse 
During preparation of adult brain sections, we noticed a striking 
difference between the brains of Nrg3-/- mice and their control littermates. Prior 
to any stains, Nrg3-/- mice consistently exhibited a region of intense white color 
in the midline (see Figure 4-11) that was fainter in the Nrg3+/+ mice. The Johns 
Hopkins Phenotyping Core examined our mice and reported that differences 
between mice may be attributable to artifacts, so we are preparing more mice in 
order to further explore this finding. At this time, however, we are unable to 
conclude that there is a gross neuroanatomical difference due to genotype, and 
we are considering alternative imaging techniques to study this question. 
 
Parvalbumin-positive cells in Adult and Adolescent Nrg3-/- mutant mice 
To assay for migratory changes in GABAergic interneurons, we marked 
cells exiting the cell cycle at E12.5 with EdU64, a thymidine analog, and followed 
them until P27 and P61. At P27 and P61, coronal sections were collected from 
the extracted brains of Nrg3-/- and wildtype control animals and labeled for EdU 
and parvalbumin (PV). Three sections were selected at different anterior-to-
posterior regions (at approximately 1.2, -0.9, and -190 from bregma), and on 
72 
 
each section 2 separate images were recorded, one of the entire cortical 
thickness from ventricle to pia in the primary or secondary somatosensory 
cortex and one in the striatum or striatum and internal capsule. For each 
image, the PV and Edu double positive and total PV positive cells were identified 
and counted. Two separate measurements were recorded for each image: the 
total number of PV-positive cells, and the percentage of EdU labeled PV cells. 
The first measurement was an indication of whether the overall PV cell 
population was altered, and the percentage a measure of how many of those 
PV+ interneurons were born at E12.5. 
In the cortical regions, we found a trend towards an increased number 
of PV+ cells in the cortex in Nrg3-/- mutant mice (Figure 4-12 D and E, Figure 4-
13). These changes reached significance in the posterior-most section at P27 (2-
tailed t-test p=0.03) and trended toward significance in the anterior-most 
section at P61 (p=0.067). Therefore, loss of Nrg3 did not lead to a deficit in PV+ 
GABAergic interneurons in the cortex, but rather, may have lead to excess 
when compared to the control. Next, we evaluated the percentage of PV cells 
exiting the cell cycle at E12.5 in the cortical regions studied (Figure 4-12 A and 
B). There was a trend towards a greater percentage of the PV+ cells marked at 
E12.5 in Nrg3-/- animals compared to controls at P27. The anterior-most region 
showed the greatest percentage of PV+/EdU+ double positive cells (p = 0.06). 
This slight trend was not evident at P61, where the percentage was similar in 
Nrg3-/- and control animals.  
Interestingly in the striatum (Figure 4-14), we found fewer PV+ cells in 
the anterior-most region in Nrg3-/- mutants in comparison to the control at P27 
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(p=0.047). However, this trend was not evident in other sections at P27 or at 
P61. In addition, there was no change in the percentage of PV+ cells born at 
E12.5, at P27 or P61. 
Together, these data suggest that more PV+ cells were born at E12.5 
and migrated to the cortex at the expense of losing cells in the striatum. 
Altogether, the adolescent and adult timepoints suggested several possible 
mechanisms mediating the changes observed in the Nrg3-/- animals.  
First, if the number of GABAergic interneuron precursor cells arising 
from the MGE is less, GABAergic interneuron precursor cells may be migrating 
in an unchanged fashion, but differentiating such that the smaller cohort of 
precursors is preferentially contributing to cortical PV+ interneurons perhaps at 
the expense of other cell fates. Alternatively, if the number of GABAergic 
interneuron precursor cells arising from the MGE is greater, GABAergic 
interneuron precursor cells may be migrating in an unchanged fashion, but the 
developing MGE compensated for Nrg3 depletion early in development by 
increasing proliferation before E12.5. In this scenario, even though the 
percentage of MGE cells born at E12.5 would be lower in Nrg3-/- mice, the total 
amount of interneuron progenitor cells overall may be significantly greater in 
Nrg3-/- mice. Finally, if the number of GABAergic interneuron precursor cells 
arising from the MGE is unchanged, GABAergic interneuron precursor cells may 
be migrating such that they are preferentially converging in the cortex of the 




Migration of Parvalbumin-positive interneurons during embryogenesis 
To test the three hypotheses, we evaluated the GABAergic interneuron 
progenitors during embryonic and early postnatal development. Since the PV 
marker was not expressed during the embryonic or early postnatal stages, we 
used Nkx2.1 as a marker for interneuron precursors. Nkx2.1 is a transcription 
factor expressed in the MGE in the cells that will become cortical neurons 
expressing either PV or somatostatin. Nkx2.1 acts on another transcription 
factor, Lhx6, a key player in determining interneuron fate.65 
         In order to study the migration of GABAergic interneuron precursors 
during embryogenesis, we marked cells exiting the cell cycle at E12.5 as before 
and sacrificed mice at E18 and P0. Similarly, three sections per animals were 
chosen at different anterior-to-posterior regions (at approximately 1.3, -0.9, and 
-2.9 mm from bregma). We labeled sections with Nkx2.1 and EdU and 
measured the Nkx2.1 and EdU double positive area and the total Nkx2.1 area 
in each image to calculate the percentage of the interneuron precursors that 
were born at E12.5. At E18, less Nkx2.1+ area overlapped with EdU in the 
anterior and posterior cortex, indicating less proliferation of the interneuron 
progenitors (Figure 4-15 B and D). At P0 (Figure 4-15 C and E), we observed a 
noticeable decrease in the mid cortex; however, these differences were not 
statistically significant. Interestingly, when the absolute area of Nkx2.1 and 
EdU double-positive cells was measured (as opposed to the percentage 
described above), the difference between Nrg3-/- and controls in the mid region 
of the cortex at P0 became statistically significant (2-tailed t-test p=0.018). 
Therefore, it appears that there were slightly fewer Nkx2.1-positive cells exiting 
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the cell cycle at E12.5. Overall in the cortex, the trend was towards fewer 
Nkx2.1 cells exiting the cell cycle at E12.5 in the Nrg3-/- animals. Of course, our 
experiment only assays cells born at E12.5, so increased proliferation prior to 
that would not be taken into account and must remain a possibility.  
To further narrow down a possible mechanism, we also evaluated the 
total Nkx2.1+ area (in pixels) in each of the images. The E18 mid-cortical region 
demonstrated lower total Nkx2.1 expression in the NRG3-/- animals (t-test, p= 
0.019). But no other regions were different between control and Nrg3-/- 
littermates. Surprisingly, there were not just fewer Nkx2.1+ cells exiting the cell 
cycle at E12.5, but, at E18 in the mid-cortex region, there are also fewer overall 
Nkx2.1+ cells. 
          Given this result, we eliminated the second hypothesis (increased 
proliferation prior to E12.5), because the Nrg3-/- mice did not exhibit greater 
overall Nkx2.1 expression. To differentiate between the other possible 
mechanisms, we examined a region of the striatum. In the first hypothesis (a 
greater number of Nkx2.1-positive cells become interneurons at the expense of 
other cell fates) migration was not necessarily affected, so we would not have 
expected to see changes in PV+ cells elsewhere In our third hypothesis (PV-
positive cells converge in the cortex), we expected to see a depletion of PV+ cells 
in some regions in the NRG3-/- animal. 
         At E18 (Figure 4-16 B and D), we found a smaller percentage of the 
Nkx2.1-positive cells were born at E12.5 in the striatum in Nrg3-/- mice (2-tailed 
t-test p=0.007). The area of Nkx2.1-positive signal was likewise smaller in the 
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Nrg3-/- animals at E18, but this result was not statistically significant. At P0 
(Figure 4-16 C and E), we observed an equal or smaller absolute area of 
Nkx2.1+ signal in the Nrg3-/- mice, although these differences were not 
significant. However, there was a trend towards a greater percentage of the 
Nkx2.1 cells that were present at that time to have been born at E12.5 in Nrg3-
/- mice. This may suggest that there was a slight increase in proliferation near 
the MGE around P0 that makes up for equal or less proliferation of these cells 
at E18. In contrast, there were significantly fewer PV+ cells in the same region 
of the striatum at P27 in the Nrg3-/- animals (p<0.05). This suggests that even if 
there was an increase in proliferation in Nkx2.1 cells at P0, the PV-positive cells 
did not remain in this region as they did in the control littermates. Therefore, 
these finding support the first hypothesis, that there is a migratory difference in 
the GABAergic interneurons that populate the cortex. The data suggest that the 
difference may have been due to a preferential convergence into cortical regions 
at the expense of other more subcortical regions. Therefore, while we expected 
to observe fewer PV+ cells in the cortex in the absence of Nrg3 due to 
migrational deficits, we uncovered a more complex mechanism. We propose that 
in the absence of Nrg3, the number of GABAergic interneuron precursors born 
in the MGE remains the same or is slightly lower. During migration (assayed at 
E18 and P0), the precursors migrate in a tangential fashion to the cortex. 
However, our data suggest that in the Nrg3-deficient brain, migration may be 
altered such that GABAergic interneurons converge in the cortical structure at 







Our behavioral studies demonstrate a pervasive hyperactivity phenotype 
in the Nrg3-/- mice. This conclusion is supported by our results in Open Field, 
Fear Conditioning, and 24-hour Circadian Rhythm tests and is consistent with 
many mouse models of other NRG/ErbB pathway genes. Gerlai et al.72 reported 
“findings that suggest a consistent hyperactivity across tests” in a heterozygous 
mutant Nrg1 mouse model. Heterozygotes were used because homozygotes did 
not survive to term. Nrg1 hypomorph mice also exhibit hyperactivity in tests 
such as open field and Y-maze.23 
An ErbB4 conditional knock-out mouse developed to express no ErbB4 in 
neurons and glia, but heterozygous for the ErbB4 null allele elsewhere to allow 
viability, also expressed a hyperactive phenotype.73 Pre-weaned ErbB4 KO mice 
scored significantly greater than controls in horizontal activity, and trended 
towards higher levels of grooming, rearing and sitting, although this effect 
reversed as adults. A different ErbB4 conditional knockout mouse, PV-ErbB4-/-, 
displayed a hyperactivity phenotype as well.74   
BACE1catalyzes cleavage of full-length Nrg3 with release of the 
extracellular EGF domain75, and Bace1-/- mice exhibited reproducible 
hyperactivity (novelty-induced, in particular) in a number of tests, including 





As mentioned previously, impaired PPI is highly valued as an 
endophenotype of human SZ that is often observed in mouse models of SZ.59,60 
In our experiments, we see a deficit in pre-pulse inhibition in our Nrg3-/- mice of 
mixed-strain backgrounds.  
Similarly, locomotor hyperactivity is also seen in mice deficient in other 
genes in the NRG/ErbB4 pathway. The Bace1-/- mouse model described above 
exhibits, in addition to hyperactivity, a deficit in PPI.76 A mouse model 
engineered to lack both ErbB2 and ErbB4 expression in the CNS resulted in 
decreased PPI in males,77 as did the the PV-ErbB4-/- mouse model.74 A Nrg1 
hypomorphic mouse23 has also been reported to be deficient in PPI.         
 
Anxiety and memory  
 Findings from our Y maze suggest that the Nrg3-/- mice may experience 
memory deficits in emotional or fearsome conditions. However, further 
experimentation with a greater number of mice is required to confirm these 
findings. 
Elevated plus maze experiments revealed a trend towards decreased anxiety, 
but like the memory findings, a greater number of mice are required to confirm 





MK-801 and GABAergic interneurons 
 As a non-competitive antagonist of the NMDA receptor, MK-801 
sensitivity in our mouse model may prove some insight into possible 
deficiencies in the Nrg3-/- mouse, which may have abnormalities in GABAergic 
interneuron migration. 
 One possible hypothesis is that reduced NMDA receptor activity affects 
primarily the function of cortical GABAergic interneurons and may lead to the 
development of SZ-like symptoms, perhaps through disrupting gamma-
frequency oscillations and, in turn, disrupting proper cortical function.78 This 
hypothesis is particularly attractive when we take into consideration the early-
adulthood age of onset of SZ symptoms, since GABAergic neurons do not 
complete their innervations until after adolescence.78 
  Nakazawa et al.78 point out three different lines of evidence for this 
hypothesis: administration of NMDAR antagonists causes a net excitatory 
change in the cortex; hippocampal GABAergic hypersensitivity to NMDAR 
antagonists when compared to pyramidal neurons; and chronic NMDAR 
antagonist use results in lower expression of GAD67 (an enzyme that converts 
glutamate to GABA) and PV in GABAergic neurons of the cortex. 
 
Interneuron Migration 
 We conclude that, as previously reported30, our Nrg3-/-mouse exhibits 
features consistent with abnormal migration of GABAergic interneurons and/or 
their precursors. However, we hypothesized that the migratory defects would 
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lead to decreased GABAergic interneurons in the cortex, a finding that we did 
not observe. We postulate that GABAergic interneuron precursors are born in 
less or equal numbers in the MGE, but a greater percentage of them migrate to 
the cortical regions at the expense of subcortical regions. The net effect is an 
increase in the number of PV+ cells in the cortical regions examined.  
 
GABAergic interneurons and behavioral abnormalities 
Yee et al.79 report that depletion of α3 GABAA receptors leads to a phenotype 
reminiscent of our Nrg3-/- mouse, with hyperactivity and startle response and 
prepulse inhibition abnormalities. This finding supports our hypothesis that 
GABAergic interneuron abnormalities may underlie the behavioral changes seen 
in Nrg3-/- mice.  
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Figure 4-1:Schematic of knockdown strategy 
Figure 4-1: Schematic of knockdown strategy.  Exon 2 of murine Nrg3 
(GRCm38/mm10 Chr14:39,011,969-39,012,099) was targeted for deletion 
using a Neomycin cassette (Neo) flanked by both FRT and LoxP sites (see 


















Figure 4-2: Northern Blots 
 
Figure 4-2: Northern Blots. RNA extracted from whole brains of E14 (lanes 
1-3), E16 (lanes 4-6), E18 (lanes 7-9), P1 (lanes 10-12) and P3 (13-15) 
Nrg3+/+ (lanes 1, 4, 7, 10 and 13), Nrg3+/- (lanes 2, 5, 8, 11, and 14) and 
Nrg3-/- (lanes 3, 6, 9, 12 and 15) was probed with Nrg3, Nrg1, ErbB4, and 







Figure 4-3: Pre-pulse inhibition of the Startle Response 
 
Figure 4-3: Pre-pulse inhibition of the startle response. (A and B) Startle 
response of mixed-background and backcrossed Nrg3-/- and Nrg3+/+ male (A) 
and female (B) mice. %PPI was calculated for mixed background (C and D) and 







Figure 4-4: Fear Conditioning 
 
Figure 4-4: Fear Conditioning. Percentage freezing behavior per minute was 
recorded for Day 1 (A), Day 2 (B) and Day 3 (C) of testing. Grey box denotes 







Figure 4-5: Hotplate Nociception Test 
 
Figure 4-5: Hotplate Nociception Test. Nrg3-/- and Nrg3+/+ mice were tested 
for nociception by measuring the latency between stimulus and response. 







Figure 4-6: 24-hour Circadian Rhythm 
  
 Figure 4-6. 24-hour circadian rhythm. Activity of male (A) and female (B) 
Nrg3-/- and Nrg3+/+ mice was tested during a 24-hour period by measuring 







Figure 4-7: Open Field 
 
Figure 4-7. Open Field. Total activity (A), percentage central activity (B) 
and rearing activity (C) of Nrg3-/- and Nrg3+/+ male mice was scored by 
number of photocell beam breaks per five-minute interval. (D) The least-
squares mean of the total activity as measured in beam breaks was 
calculated for baseline and post-MK801 injection periods. Baseline 
percentage of central activity (E) was measured according to genotype by 
recording photocell beam breaks. (F) Total, central and peripheral activity 





Figure 4-8: MK801 Sensitivity in Open Field 
 
Figure 4-8. MK801 sensitivity during Open Field experiment. Total 
activity of Nrg3-/- and Nrg3+/+ male mice was scored by number of photocell 
beam breaks per five-minute interval. Blocks of time shaded in pink were 







Figure 4-9: Elevated Plus Maze 
 
Figure 4-9. Elevated Plus Maze. Percentage of time Nrg3-/- and Nrg3+/+ mice 















Figure 4-10: Y-Maze 
 
Figure 4-10. Y-Maze. Nrg3-/- and Nrg3+/+ mice of either sex were subjected 
to a Y Maze. (A) Absolute time (in seconds) spent in blocked and open arms 
of the Y Maze. (B) Number of triad and non-triad alterations during Y Maze 




Figure 4-11: Gross Neuroanatomy of Nrg3-/- and Nrg3+/+ mice 
 
Figure 4-11. Gross Neuroanatomy of Nrg3-/- and Nrg3+/+ mice. Phase 
contrast microscopy of equivalent vibratome sections from P61 Nrg3+/+ 
(WT) and Nrg3-/- (KO) mice at two different depths anterior to posterior 








Figure 4-12: Cortical Region of Adult and Adolescent Brains 
 
Figure 4-12. Cortical regions of adult and adolescent brains. Microscopic 
images of cortical regions defined in (A) were examined for (B and C) the 
percentage of cells staining positive for parvalbumin (PV) that also stained 
positive for EdU and (D and E) number of cells staining positive for PV. 
Measurements were performed at Postnatal days (B and D) 27 and (C and 




Figure 4-13: Microscopy of Cortical Regions of Adult and Adolescent 
Brains 
 
Figure 4-13. Microscopy of cortical regions of adult and adolescent brains. 
Microscopic images of equivalent regions of cortex in Nrg3-/- and Nrg3+/+ 
mice at P27 and P61 ages. Arrowhead denotes a cell tallied as double-




Figure 4-14: Subcortical Regions of Adult and Adolescent Brains 
 
Figure 4-14. Subcortical regions of adult and adolescent brains. 
Microscopic images of subcortical regions defined in (A) were examined for 
(B and C) the percentage of cells staining positive for parvalbumin (PV) 
that also stained positive for EdU and (D and E) number of cells staining 
positive for PV. Measurements were performed at Postnatal days (B and D) 





Figure 4-15: Cortical Regions of Brain during Embryogenesis 
 
Figure 4-15. Cortical regions of brain during embryogenesis. Microscopic 
images of cortical regions defined in (A) were examined for (B and C) 
absolute area staining positive for both Nkx2.1 and EdU, as measured in 
arbitrary units and (D and E) the percentage of area staining positive for 
Nkx2.1 that also stained positive for EdU. Measurements were performed 
for (B and D) embryonic day 18 fetuses and (C and E) early post-natal  








Figure 4-16: Subcortical Regions of Brain during Embryogenesis 
 
Figure 4-16. Subcortical regions of brain during embryogenesis. 
Microscopic images of subcortical regions defined in (A) were examined for 
(B and C) the percentage of area staining positive for Nkx2.1 that also 
stained positive for EdU and (D and E) absolute area staining positive for 
both Nkx2.1 and EdU, as measured in arbitrary units. Measurements were 
performed for (B and D) embryonic day 18 fetuses and (C and E) early post-






Table 4-1: Summary of Histological Changes in cortex of Nrg3-/- mice 
 
Table 4-1. Summary of histological changes in the cortex of Nrg3-/- +/+ 
adult and adolescent mice. Observed trends in percentage of parvalbumin 
(PV)-positive cells that also stained positive for EdU and absolute number 
of PV-positive cells in the anterior, mid and posterior sections of P27 and 
P61 mice examined. All trends are in relation to wildtype littermates. 
Asterisk (*) denotes a statistically-significant difference, parentheses a 





Table 4-2: Summary of Histological Changes in striatum of Nrg3-/- mice 
 
Table 4-2. Summary of histological changes in the striatum of Nrg3-/- adult 
and adolescent mice. Observed trends in percentage of parvalbumin (PV)-
positive cells that also stained positive for EdU and absolute number of 
PV-positive cells in the anterior, mid and posterior sections of P27 and 
P61 mice examined. All trends are in relation to wildtype littermates. 
Asterisk (*) denotes a statistically-significant difference, parentheses a 




Chapter 5 : Conclusion 
Summary 
The thesis of my dissertation is that variants in NRG3 affect the 
expression and/or splicing of this gene. Regulatory imbalances in NRG3 
absolute levels or relative isoform abundance lead to a predisposition to a 
subtype of SZ that exhibits more types of delusions. This effect is mediated by 
improper neural migration during development.  
 In Chapter 2, I sequenced a 162 Kb LD block covering the 5’ end of NRG3 
associated with risk for delusions in the context of SZ and identify those 
variants driving the association signal. For three of those SNP variants, in a 
number of cell types, I then show evidence for genotype affecting the regulation 
of a downstream reporter gene. These SNPs also spear to affect the relative 
abundance of various transcripts of this gene.  
 In Chapter 3, I provide evidence that at least one nuclear protein binds 
each 21-bp probe containing the SNP. In two of the SNPs, the allele of the SNP 
affects protein binding, by changing the shifting pattern and/or intensity of the 
observed bands.  Bioinformatical analyses reach the same conclusion regarding 
allele affecting protein binding as our experiments, and suggest possible protein 
candidates to test for binding. I tested one candidate, CNOT4, by EMSA 
supershift and conclude that the SNP may be mediating the risk for delusions 
by preferential binding of this transcription factor complex member. Future 
experiments are planned for confirmation. 
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 In Chapter 4, I characterize a Nrg3 knockout mouse through behavioral 
and neuromigratory experiments. I find a pervasive hyperactive phenotype seen 
in many other animal models deficient in genes in the same pathway. 
Additionally, we find a modest deficit in PPI and startle response, as well as 
decreased anxiety, fear and/or emotional- based learning or memory deficits, 
and perturbed working memory. I also test the hypothesis that depletion of 
Nrg3 in the developing brain produces an animal deficient in cortical GABAergic 
interneurons. I find that although there is evidence for differences in migratory 
patterns, no cortical depletion of these cells is observed. However, a depletion of 
PV-positive cells in the striatum suggests a compensatory mechanism that 
results in altered migration.  
 
Future and Ongoing Work 
 At the time of publication, a number of experiments are underway that 
will further inform this thesis.  
 In order to generate more hypotheses about proteins potentially binding 
the intronic regions of the SNPs identified in Chapter 2, I have an ongoing 
protein microarray experiment in which we will probe an array of human 
transcription factors with labeled probes containing our regions of interest. 
Observation that CNOT4 binds our probes in an allele-specific fashion will 
support the evidence presented in Chapter 3. If not, other candidate 
transcription factors may come out of this experiment that can be tested 




 Finally, we are expanding our mouse colonies in order to increase the 
number of mice tested for behavioral traits, neuromigratory changes, and gross 
morphological differences. For those behavioral experiments in which we see a 
trend, we believe that increasing the number of subjects will help to determine 
whether the differences we believe we see are statistically significant. We are 
also expecting to increase the number of P61 mice injected with EdU while in 
utero, in order to assess whether the gross neuromorphological changes 
described in Chapter 4 are reproducible. We plan to use the same mice to 
increase the number of subjects in our imaging studies, and perhaps study 
different regions of the cortex and striatum more systematically.  
 Another interesting experiment to consider is backcrossing the mixed-
strain background to a strain (such as a 129 strain80) that has a naturally high 
startle response. This may uncover the deficit in PPI that may have been 
obscured due to the low startle response of C57BL/6J strain.80  
Contributions  
In my dissertation, I have specifically contributed: 
 New, inclusive nomenclature of all known exons of NRG3 
 Identification of causative variants in the association of the NRG3 
gene with the delusion factor in SZ 
 Evidence of the regulatory effect of intronic SNPs in NRG3 
 Exploration of putative transcription factors that bind regulatory 
SNPs and thus mediate the effect of NRG3 on SZ 
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 Characterization of neurodevelopmental phenotype of a Nrg3 
knockout mouse 
 Analysis of results of behavioral experiments conducted on a Nrg3 
knockout mouse  
As a whole, my thesis takes an unconventionally deep approach to 
association studies. I begin with a region (162 kb LD block) associated with a 
trait (delusion), I identify all variants in our cohort, rank those variants by 
strength of association, and demonstrate a regulatory role for three of them. I 
then explore the mechanism whereby those SNPs appear to be modifying the SZ 
phenotype in patients, testing for preferential binding and relative transcript 
abundance changes influenced by genotype at those SNPs. I attempt to identify 
the protein I surmise to be binding our region of interest by a combined 
bioinformatics and experimental approach. 
  Studies such as these, where we follow up association results to find 
causative variants, are going to become increasingly more important in helping 
us identify specific polymorphisms that modulate SZ risk, as opposed to genes 
that mediate risk for the disease. In an age of genomics and whole genome 
sequencing, better understanding how each of the many SZ risk genes mediates 
its effect on the phenotype is going to become crucial in counseling patients 
that harbor variants of unknown significance in SZ risk genes.  
 Additionally, focusing on specific phenotypic traits, such as our delusion 
factor, rather than a binary diagnostic classification, can help to reduce the 
noise introduced by empirically-determined diagnostic categories and may 
provide more power to studies with limited subjects. This approach may also be 
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important in helping us understand the pathways and mechanisms involved in 
the components of this disease. This approach should better identify key 
biomarkers for detecting risk of specific symptoms, may improve our ability to 
generate and tailor drugs for the individual patient’s presenting symptoms 
(rather than for a “textbook case” of SZ) and will help us better understand the 
normal mechanisms that go awry in SZ and other psychiatric diseases in a way 
that studying SZ as a binary entity has not. This “endophenotype” approach 
has recently been espoused by the National Institutes of Mental Health81.  
 My thesis also contributes to the field by describing a Nrg3 mouse model 
for SZ. Behavioral tests conducted demonstrate a number of relevant 
phenotypes, most noticeably hyperactivity, consistent with other mouse models 
of this pathway. I suspect that the Nrg3-/- mouse does have abnormal 
interneuron migratory patterns, but the end result of this defect is a 
comparable or greater number of GABAergic interneurons in the cortex. These 
abnormalities may explain why the mouse is not as debilitated as one might 
expect. Nonetheless, we believe that this mouse strain is a valuable mouse 
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